0001558370-23-008308.txt : 20230505 0001558370-23-008308.hdr.sgml : 20230505 20230505161603 ACCESSION NUMBER: 0001558370-23-008308 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230505 DATE AS OF CHANGE: 20230505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Editas Medicine, Inc. CENTRAL INDEX KEY: 0001650664 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464097528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37687 FILM NUMBER: 23894051 BUSINESS ADDRESS: STREET 1: 11 HURLEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-401-9000 MAIL ADDRESS: STREET 1: 11 HURLEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02141 10-Q 1 edit-20230331x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ________

Commission File Number 001-37687

EDITAS MEDICINE, INC.

(Exact name of registrant as specified in its charter)


Delaware (State or other jurisdiction of incorporation or organization)		46-4097528 (I.R.S. Employer Identification No.)

11 Hurley Street Cambridge, Massachusetts (Address of principal executive offices)		02141 (Zip Code)

(617) 401-9000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	EDIT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	⌧	Accelerated filer	◻

Non-accelerated filer	◻	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

The number of shares of Common Stock outstanding as of April 28, 2023 was 68,995,606.

Table of Contents

Editas Medicine, Inc.

TABLE OF CONTENTS


		Page

PART I. FINANCIAL INFORMATION		3

Item 1.	Financial Statements (unaudited)	3
	Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022	3
	Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022	4
	Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2023 and 2022	5
	Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2023 and 2022	6
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022	7
	Notes to Condensed Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24
Item 4.	Controls and Procedures	24

PART II. OTHER INFORMATION		25

Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 6.	Exhibits	25

Signatures		27

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

Editas Medicine, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(amounts in thousands, except share and per share data)


	March 31,		December 31,
	2023		2022
ASSETS
Current assets:
Cash and cash equivalents	$	129,021	$	141,522
Marketable securities		189,418		202,752
Accounts receivable		242		5,145
Prepaid expenses and other current assets		5,777		7,335
Total current assets		324,458		356,754
Marketable securities		83,339		93,097
Property and equipment, net		13,211		15,569
Right-of-use assets		36,344		43,648
Restricted cash and other non-current assets		6,753		5,253
Total assets	$	464,105	$	514,321
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	9,047	$	9,511
Accrued expenses		31,560		31,296
Deferred revenue, current		8,221		8,221
Operating lease liabilities		8,327		11,082
Total current liabilities		57,155		60,110
Operating lease liabilities, net of current portion		28,810		32,864
Deferred revenue, net of current portion		60,667		60,667
Total liabilities		146,632		153,641
Stockholders’ equity
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding		—		—
Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 68,993,591 and 68,847,382 shares issued, and 68,993,591 and 68,847,382 shares outstanding at March 31, 2023 and December 31, 2022, respectively		7		7
Additional paid-in capital		1,446,912		1,442,405
Accumulated other comprehensive loss		(2,279)		(3,601)
Accumulated deficit		(1,127,167)		(1,078,131)
Total stockholders’ equity		317,473		360,680
Total liabilities and stockholders’ equity	$	464,105	$	514,321

The accompanying notes are an integral part of the condensed consolidated financial statements.

Table of Contents

Editas Medicine, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(amounts in thousands, except share and per share data)


	Three Months Ended
	March 31,
	2023		2022
Collaboration and other research and development revenues	$	9,851	$	6,771
Operating expenses:
Research and development		37,804		37,976
General and administrative		23,008		19,545
Total operating expenses		60,812		57,521
Operating loss		(50,961)		(50,750)
Other income, net:
Other expense, net		(1,584)		(234)
Interest income, net		3,509		469
Total other income, net		1,925		235
Net loss	$	(49,036)	$	(50,515)
Net loss per share, basic and diluted	$	(0.71)	$	(0.74)
Weighted-average common shares outstanding, basic and diluted		68,924,180		68,484,978

The accompanying notes are an integral part of the condensed consolidated financial statements.

Table of Contents

Editas Medicine, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(unaudited)

(amounts in thousands)


	Three Months Ended
	March 31,
	2023		2022
Net loss	$	(49,036)	$	(50,515)
Other comprehensive loss:
Unrealized gain (loss) on marketable debt securities		1,322		(2,016)
Comprehensive loss	$	(47,714)	$	(52,531)

The accompanying notes are an integral part of the condensed consolidated financial statements.

Table of Contents

Editas Medicine, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(unaudited)

(amounts in thousands, except share data)


						Accumulated
				Additional		Other		Other		Total
	Common Stock			Paid-In		Comprehensive		Accumulated		Stockholders’
	Shares	Amount		Capital		Loss		Deficit		Equity
Balance at December 31, 2022	68,847,382	$	7	$	1,442,405	$	(3,601)	$	(1,078,131)	$	360,680
Exercise of stock options	—		—		—		—		—		—
Vesting of restricted common stock awards	146,209		—		—		—		—		—
Stock-based compensation expense	—		—		4,507		—		—		4,507
Unrealized gain on marketable debt securities	—		—		—		1,322		—		1,322
Net loss	—		—		—		—		(49,036)		(49,036)
Balance at March 31, 2023	68,993,591	$	7	$	1,446,912	$	(2,279)	$	(1,127,167)	$	317,473



						Accumulated
				Additional		Other		Other		Total
	Common Stock			Paid-In		Comprehensive		Accumulated		Stockholders’
	Shares	Amount		Capital		Loss		Deficit		Equity
Balance at December 31, 2021	68,435,257	$	7	$	1,411,827	$	(493)	$	(857,699)	$	553,642
Exercise of stock options	12,573		—		218		—		—		218
Vesting of restricted common stock awards	154,834		—		—		—		—		—
Stock-based compensation expense	—		—		11,431		—		—		11,431
Unrealized loss on marketable debt securities	—		—		—		(2,016)		—		(2,016)
Net loss	—		—		—		—		(50,515)		(50,515)
Balance at March 31, 2022	68,602,664	$	7	$	1,423,476	$	(2,509)	$	(908,214)	$	512,760

The accompanying notes are an integral part of the condensed consolidated financial statements.

Table of Contents

Editas Medicine, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(amounts in thousands)


	Three Months Ended
	March 31,
	2023		2022
Cash flow from operating activities
Net loss	$	(49,036)	$	(50,515)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		4,507		11,431
Depreciation		1,544		1,558
Loss on disposal of fixed assets		1,583		—
Other non-cash items, net		(693)		234
Changes in operating assets and liabilities:
Accounts receivable		4,903		(1,105)
Prepaid expenses and other current assets		1,558		(99)
Right-of-use assets		7,304		2,716
Other non-current assets		(1,500)		(505)
Accounts payable		(557)		(229)
Accrued expenses		1,427		(3,982)
Deferred revenue		—		(5,516)
Operating lease liabilities		(6,808)		(3,215)
Net cash used in operating activities		(35,768)		(49,227)
Cash flow from investing activities
Purchases of property and equipment		(1,840)		(2,248)
Purchases of marketable securities		(40,798)		(60,381)
Proceeds from maturities of marketable securities		65,905		119,000
Net cash provided by investing activities		23,267		56,371
Cash flow from financing activities
Proceeds from exercise of stock options		—		218
Net cash provided by financing activities		—		218
Net (decrease) increase in cash, cash equivalents, and restricted cash		(12,501)		7,362
Cash, cash equivalents, and restricted cash, beginning of period		145,399		207,396
Cash, cash equivalents, and restricted cash, end of period	$	132,898	$	214,758
Supplemental disclosure of cash and non-cash activities:
Fixed asset additions included in accounts payable and accrued expenses	$	370	$	199
Cash paid in connection with operating lease liabilities		3,897		3,746
Remeasurement of operating lease liabilities and right-of-use assets due to lease modification		(3,781)		—

The accompanying notes are an integral part of the condensed consolidated financial statements.

Table of Contents

Editas Medicine, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. Nature of Business

Editas Medicine, Inc. (the “Company”) is a clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.

Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc., a wholly-owned subsidiary of the Bristol-Myers Squibb Company (“BMS”), and payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, which was terminated in August 2020.

The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.

Liquidity

In May 2021, the Company entered into a common stock sales agreement with Cowen and Company, LLC (“Cowen”), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million (the “ATM Facility”). As of March 31, 2023, the Company has not sold any shares of its common stock under the ATM Facility.

The Company has incurred annual net operating losses in every year since its inception. The Company expects that its existing cash, cash equivalents and marketable securities at March 31, 2023 will enable it to fund its operating expenses and capital expenditure requirements into 2025. The Company had an accumulated deficit of $1.1 billion at March 31, 2023, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.

2. Summary of Significant Accounting Policies

Unaudited Interim Financial Information

The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”).

Table of Contents

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Editas Securities Corporation and Editas Medicine, LLC. All intercompany transactions and balances of the subsidiaries have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended March 31, 2023 and 2022 are referred to as the first quarter of 2023 and 2022, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.

Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” to the consolidated financial statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report.

3. Cash Equivalents and Marketable Securities

Cash equivalents and marketable securities consisted of the following at March 31, 2023 (in thousands):


			Allowance		Gross		Gross
	Amortized		for Credit		Unrealized		Unrealized		Fair
March 31, 2023	Cost		Losses		Gains		Losses		Value
Cash equivalents and marketable securities:
Government agency securities	$	176,982	$	—	$	42	$	(1,757)	$	175,267
Money market funds		129,021		—		—		—		129,021
Corporate notes/bonds		55,876		—		24		(477)		55,423
Commercial paper		29,809		—		—		(63)		29,746
U.S. Treasuries		12,369		—		—		(48)		12,321
Total	$	404,057	$	—	$	66	$	(2,345)	$	401,778

Cash equivalents and marketable securities consisted of the following at December 31, 2022 (in thousands):


			Allowance		Gross		Gross
	Amortized		for Credit		Unrealized		Unrealized		Fair
December 31, 2022	Cost		Losses		Gains		Losses		Value
Cash equivalents and marketable securities:
Government agency securities	$	161,902	$	—	$	11	$	(2,556)	$	159,357
Money market funds		141,522		—		—		—		141,522
Corporate notes/bonds		57,575		—		2		(694)		56,883
U.S. Treasuries		50,019		—		3		(229)		49,793
Commercial paper		29,954		—		3		(141)		29,816
Total	$	440,972	$	—	$	19	$	(3,620)	$	437,371

As of March 31, 2023, the Company did not hold any marketable securities that had been in an unrealized loss position for more than twelve months. Furthermore, the Company has determined that there were no material changes in the credit risk of the debt securities. As of March 31, 2023, the Company holds 56 securities with an aggregate fair value of $83.3 million that had remaining maturities greater than one year.

There were no realized gains or losses on available-for-sale securities during the three months ended March 31, 2023 and 2022.

Table of Contents

4. Fair Value Measurements

Assets measured at fair value on a recurring basis as of March 31, 2023 were as follows (in thousands):


			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
	March 31,		Identical Assets		Inputs		Inputs
Financial Assets	2023		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	129,021	$	129,021	$	—	$	—
Marketable securities:
Government agency securities		175,267		—		175,267		—
Corporate notes/bonds		55,423		—		55,423		—
Commercial paper		29,746		—		29,746		—
U.S. Treasuries		12,321		12,321		—		—
Restricted cash and other non-current assets:
Money market funds		3,877		3,877		—		—
Total financial assets	$	405,655	$	145,219	$	260,436	$	—

Assets measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):


			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
	December 31,		Identical Assets		Inputs		Inputs
Financial Assets	2022		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	141,522	$	141,522	$	—	$	—
Marketable securities:
Government agency securities		159,357		—		159,357		—
Corporate bonds		56,883		—		56,883		—
U.S. Treasuries		49,793		49,793		—		—
Commercial paper		29,816		—		29,816		—
Restricted cash and other non-current assets:
Money market funds		3,877		3,877		—		—
Total financial assets	$	441,248	$	195,192	$	246,056	$	—

5. Accrued Expenses

Accrued expenses consisted of the following (in thousands):


	As of
	March 31,		December 31,
	2023		2022
External research and development expenses	$	21,761	$	16,452
Employee related expenses		5,956		10,140
Intellectual property and patent related fees		2,168		1,809
Professional service expenses		1,566		1,260
Other expenses		109		1,635
Total accrued expenses	$	31,560	$	31,296

Table of Contents

6. Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):


	As of
	March 31,		December 31,
	2023		2022
Laboratory equipment	$	23,813	$	24,407
Leasehold improvements		9,634		9,761
Computer equipment		875		875
Construction-in-progress		369		1,573
Furniture and office equipment		264		264
Software		215		215
Total property and equipment		35,170		37,095
Less: accumulated depreciation		(21,959)		(21,526)
Property and equipment, net	$	13,211	$	15,569

7. Commitments and Contingencies

The Company is a party to a number of license agreements under which the Company licenses patents, patent applications and other intellectual property from third parties. As such, the Company is obligated to pay licensors for various costs including upfront licenses fees, annual license fees, certain licensor expense reimbursements, success payments, research funding payments, and milestones triggerable upon certain development, regulatory, and commercial events as well as royalties on future products. These contracts are generally cancellable, with notice, at the Company’s option and do not have significant cancellation penalties. The terms and conditions as well as the accounting analysis for the Company’s significant commitments and contingencies are described in Note 8, “Commitments and Contingencies” to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.

Licensor Expense Reimbursement

The Company is obligated to reimburse The Broad Institute, Inc. (“Broad”) and the President and Fellows of Harvard College (“Harvard”) for expenses incurred by each of them associated with the prosecution and maintenance of the patent rights that the Company licenses from them pursuant to the license agreement by and among the Company, Broad and Harvard, including the interference and opposition proceedings involving patents licensed to the Company under the license agreement, and other license agreements between the Company and Broad. As such, the Company anticipates that it has a substantial commitment in connection with these proceedings until such time as these proceedings have been resolved, but the amount of such commitment is not determinable. The Company incurred an aggregate of $3.0 million and $2.1 million in expense during the three months ended March 31, 2023 and 2022, respectively, for such reimbursement.

8. Collaboration and Profit-Sharing Agreements

The Company has entered into multiple collaborations, out-licenses and strategic alliances with third parties that typically involve payments to or from the Company, including up-front payments, payments for research and development services, option payments, milestone payments and royalty payments to or from the Company. The terms and conditions as well as the accounting analysis for the Company’s significant collaborations, out-licenses and strategic alliances are described in Note 9, “Collaboration and Profit-Sharing Agreements” to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.

Table of Contents

Collaboration Revenue

As of March 31, 2023, the Company’s contract liabilities were primarily related to the Company’s collaboration with BMS. The following table presents changes in the Company’s accounts receivable and contract liabilities for the three months ended March 31, 2023 (in thousands):


For the three months ended March 31, 2023	Balance at December 31, 2022		Additions		Deductions		Balance at March 31, 2023
Accounts receivable	$	5,145	$	97	$	(5,000)	$	242
Contract liabilities:
Deferred revenue	$	68,888	$	—	$	—	$	68,888

During the three months ended March 31, 2023, the Company recognized the following collaboration revenue (in thousands):


	Three Months Ended
Revenue recognized in the period from:	March 31, 2023
Amounts included in deferred revenue at the beginning of the period	$	—
Performance obligations satisfied in previous periods	$	—

9. Stock-based Compensation

Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):




	Three Months Ended
	March 31,
	2023		2022
Research and development	$	2,086	$	3,695
General and administrative		2,421		7,736
Total stock-based compensation expense	$	4,507	$	11,431

Restricted Stock Unit Awards

The following is a summary of restricted stock unit awards activity for the three months ended March 31, 2023:


		Weighted
		Average
		Grant Date
		Fair Value
	Shares	Per Share
Unvested restricted stock unit awards as of December 31, 2022	1,499,070	$	18.70
Issued	884,867	$	8.64
Vested	(146,209)	$	19.52
Forfeited	(248,527)	$	21.97
Unvested restricted stock unit awards as of March 31, 2023	1,989,201	$	13.76

The restricted stock units issued in the three months ended March 31, 2023 include 253,100 units granted to certain employees that contain performance-based vesting provisions. The Company recognizes the fair value of the performance-based units through the expected achievement date if the performance-based vesting provisions are deemed probable.

As of March 31, 2023, total unrecognized compensation expense related to unvested restricted stock unit awards was $15.4 million, which the Company expects to recognize over a remaining weighted-average period of 2.85 years.

Table of Contents

Stock Options

The following is a summary of stock option activity for the three months ended March 31, 2023:


		Weighted Average		Remaining	Aggregate Intrinsic
	Shares	Exercise Price		Contractual Life (years)	Value (in thousands)
Outstanding at December 31, 2022	5,276,148	$	23.99	8.0	$	401,529
Granted	1,209,494	$	8.64
Exercised	—	$	—
Cancelled	(326,434)	$	24.56
Outstanding at March 31, 2023	6,159,208	$	20.95	7.9	$	236,504
Exercisable at March 31, 2023	2,168,910	$	30.18	6.0	$	236,504

As of March 31, 2023, total unrecognized compensation expense related to stock options was $32.6 million, which the Company expects to recognize over a remaining weighted-average period of 3.1 years.

10. Net Loss per Share

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury stock and if converted methods. Contingently issuable shares are included in the calculation of basic loss per share as of the beginning of the period in which all the necessary conditions have been satisfied. Contingently issuable shares are included in diluted loss per share based on the number of shares, if any, that would be issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, if the results are dilutive.

For purposes of the diluted net loss per share calculation, stock options are considered to be common stock equivalents, but they were excluded from the Company’s calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.

The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:


	Three months ended
	March 31,
	2023	2022
Unvested restricted stock and restricted stock unit awards	1,989,201	1,233,218
Outstanding stock options	6,159,208	3,920,083
Total	8,148,409	5,153,301

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission (“SEC”) on February 22, 2023 (the “Annual Report”).

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements addressing our future operating performance and clinical development and regulatory timelines that we expect or anticipate will occur in the future, as well as expectations for cash runway, are forward-looking statements. There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking statements, including uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of our product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail in the Annual Report under the captions “Risk Factor Summary” and Part I, “Item 1A. Risk Factors,” as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.

You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on Form 10-Q, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Overview

We are a clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. We have developed a proprietary gene editing platform based on CRISPR technology and we continue to expand its capabilities. Our product development strategy is to target diseases where gene editing can be used to enable or enhance therapeutic outcomes for patients, while maximizing probability of technical, regulatory and commercial success. We are focused on advancing gene editing medicines to treat hemoglobinopathies, beginning with the continued development of our current ex vivo EDIT-301 program and leveraging the insights gained from this program to pursue next generation in vivo gene editing medicines targeting hematopoietic stem cells (“HSCs”). In parallel, we are pursuing the development of in vivo gene editing medicines for other organs and tissues that we believe will significantly differentiate our genome editing approach from the current standards of care for serious diseases. As part of these efforts, we are using existing strategic partnerships and collaborations and pursuing further opportunities to extend the reach of our intellectual property portfolio and access complementary technologies to expedite our drug discovery and clinical execution objectives.

Our lead program, EDIT-301, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (“SCD”), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (“TDT”), the most severe form of beta-thalassemia, another inherited blood disorder characterized by severe anemia. In the second quarter of 2022, we dosed the first patient in our Phase 1/2 clinical trial of EDIT-301, which we refer to as our RUBY trial, for the treatment of severe SCD, and in December 2022, announced initial clinical data from the first two patients treated in the RUBY trial. This clinical data supports human proof of concept by showing that EDIT-301

Table of Contents

could safely increase expression of fetal hemoglobin to clinically meaningful levels and correct anemia in SCD patients. For additional information regarding these clinical data, please see “Business—Our Gene Editing Medicine Programs—Hemoglobinopathies” in the Annual Report. After completing sequential dosing of the first two patients, we commenced parallel patient dosing in the first quarter of 2023 and remain on track to dose 20 total patients by the end of 2023, with 19 patients currently enrolled in the trial. We expect to provide clinical updates from the RUBY trial in June 2023 and again by the end of 2023. In April 2023, the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug Designation to EDIT-301 for the treatment of SCD.

In December 2021, the FDA cleared our Investigational New Drug (“IND”) application for a Phase 1/2 clinical trial of EDIT-301 for the treatment of TDT. This trial, referred to as our EDITHAL trial, is designed to assess the safety, tolerability, and preliminary efficacy of EDIT-301 for the treatment of TDT. We dosed the first patient in this trial in the first quarter of 2023, and this patient had successful neutrophil and platelet engraftment. We remain on track to present data from the EDITHAL trial by the end of 2023.

We are also pursuing the development of next generation in vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. We are initially focused on editing HSCs through targeted delivery of our AsCas12a enzyme to our clinically validated HBG1 and HBG2 promotor site. We are also in the discovery stage in developing in vivo gene editing medicines for other organs and tissues.

We previously achieved human proof of concept for our most advanced in vivo gene editing medicine for inherited retinal diseases, EDIT-101 to treat Leber congenital amaurosis. In November 2022, we announced updated clinical data from our Phase 1/2 BRILLIANCE trial of EDIT-101. This data demonstrated a favorable safety profile and provided proof of concept. However, we were not able to identify any baseline characteristics of the treatment responder patients that could pre-select a responder patient population other than zygosity. The identified responder patient population was determined to be too small to progress the program independently. We have since paused patient enrollment in this program.

We are pursuing the right combination of gene editing and targeted delivery tools through internal development and the in-licensing of complementary technologies, while also leveraging our intellectual property portfolio to drive potential out-licensing and partnership discussions that can accelerate the achievement of our goal of delivering lifesaving medicines to patients with previously untreatable or under-treated diseases. In cellular therapy medicines, we are leveraging new and existing partnerships to progress engineered cell medicines to treat various cancers. We are advancing alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors in collaboration with Bristol Myers Squibb Company (“BMS”) through its wholly owned subsidiary, Juno Therapeutics, Inc. (“Juno Therapeutics”). This collaboration, which leverages our Cas9 and AsCas12a platform technologies, has resulted in 11 programs. We have also entered into a non-exclusive collaboration and licensing agreement with Immatics N.V. to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer.

In January 2023, we announced the sale of our wholly owned oncology assets to Shoreline Biosciences, Inc. (“Shoreline”). Under the agreement, Shoreline acquired EDIT-202, our preclinical multiplexed edited induced human pluripotent stem cell (“iPSC”)-derived natural killer (“iNK”) cell medicine for the treatment of solid tumors, as well as an additional iNK program under development and certain related manufacturing technologies. We also exclusively licensed to Shoreline our rights to a proprietary knock-in gene editing technology referred to as SLEEK (SeLection by Essential-gene Exon Knock-in) for use in Shoreline’s iNK platform and for oncology in Shoreline’s iPSC-derived macrophage platform, as well as non-exclusively licensed our AsCas12a gene editing technology. We believe that this transaction will enable this oncology program to more rapidly move towards clinical applications.

Since our inception in September 2013, our operations have focused on organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio, assembling our core capabilities in gene editing, seeking to identify potential product candidates, and undertaking preclinical studies. Except for EDIT-301, all of our ongoing research programs are still in the preclinical or research stage of development and the risk of failure of all of our research programs is high. We have not generated any revenue from product sales. We have primarily financed our operations through various equity financings and payments received under our research collaboration with BMS and

Table of Contents

our former strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliates, “Allergan”), which was terminated in August 2020.

Since inception, we have incurred significant operating losses. Our net losses were $49.0 million and $50.5 million for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, we had an accumulated deficit of $1.1 billion. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and from year to year. We anticipate that our expenses will increase substantially as we continue our current research programs and our preclinical development activities; progress our clinical trials; seek to identify additional research programs and additional product candidates; initiate preclinical testing and clinical trials for other product candidates we identify and develop; maintain, expand, and protect our intellectual property portfolio, including reimbursing our licensors for such expenses related to the intellectual property that we in-license from such licensors; hire additional clinical, quality control, and scientific personnel; and incur additional costs associated with operating as a public company. We do not expect to be profitable for the year ending December 31, 2023 or the foreseeable future.

We did not experience any significant impact on our financial condition, results of operations or liquidity due to the COVID-19 pandemic during the quarter ended March 31, 2023. At its height, the COVID-19 pandemic had a significant negative effect on the global economy, supply chains and labor force participation, and created significant volatility in financial markets. The extent of the future impact of the COVID-19 pandemic, or any future pandemic, on our operational and financial performance, including our ability to timely advance our clinical trials and preclinical activities, will depend on future developments, including the duration, spread and severity of the pandemic, any evolution of the virus, government restrictions imposed in response, and the availability and effectiveness of vaccines and treatment options, all of which are uncertain and cannot be predicted. We will continue to monitor and respond to the changing conditions created by the pandemic and related impacts, with focus on prioritizing the health and safety of our employees and maintaining safe and reliable operations of our facilities.

Financial Operations Overview

Revenue

To date, we have not generated any revenue from product sales and we do not expect to generate any revenue from product sales for the foreseeable future. In connection with our collaboration with BMS, we have received an aggregate of $135.0 million in payments, which have primarily consisted of the initial upfront and amendment payments, development milestone payments, research funding support and certain opt-in fees. We no longer receive research funding support from BMS. As of March 31, 2023, we recorded $56.7 million of deferred revenue in relation to our collaboration with BMS, all of which is classified as long-term on our condensed consolidated balance sheet. Under this collaboration, we will recognize revenue upon delivery of option packages to BMS or upon receipt of development milestone payments. We expect that our revenue will fluctuate from quarter-to-quarter and year-to-year as a result of the timing of when we deliver such option packages or receive such milestone payments.

For additional information about our revenue recognition policy related to the BMS collaboration, see Part II, “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates—Revenue Recognition” included in the Annual Report.

For the foreseeable future we expect substantially all of our revenue will be generated from our collaboration with BMS, and other collaborations or agreements we enter into.

Table of Contents

Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research, preclinical development, process and scale-up development, manufacture and clinical development of our product candidates, and development activities under our collaboration agreements. These costs are expensed as incurred and include:

●

employee-related expenses including salaries, benefits, and stock-based compensation expense;

●

costs under clinical trial agreements with investigative sites;

●

costs associated with conducting our preclinical, process and scale-up development, manufacturing, clinical and regulatory activities, including fees paid to third-party professional consultants, service providers and suppliers;

●

costs of purchasing lab supplies and non-capital equipment used in our preclinical activities and in manufacturing preclinical and clinical study materials;

●

costs for research and development activities under our collaboration agreements;

●

facility costs, including rent, depreciation, and maintenance expenses; and

●

fees for acquiring and maintaining licenses under our third-party licensing agreements, including any sublicensing or success payments made to our licensors.

At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of any product candidates we may identify and develop. This is due to the numerous risks and uncertainties associated with developing such product candidates, including the uncertainty of:

●

successful completion of preclinical studies, IND-enabling studies and natural history studies;

●

successful enrollment in, and completion of, clinical trials;

●

receipt of marketing approvals from applicable regulatory authorities;

●

establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;

●

obtaining and maintaining patent and trade secret protection and non-patent exclusivity;

●

launching commercial sales of a product, if and when approved, whether alone or in collaboration with others;

●

acceptance of a product, if and when approved, by patients, the medical community, and third-party payors;

●

effectively competing with other therapies and treatment options;

●

a continued acceptable safety profile following approval;

●

enforcing and defending intellectual property and proprietary rights and claims; and

Table of Contents

●

achieving desirable medicinal properties for the intended indications.

A change in the outcome of any of these variables with respect to the development of any product candidates we develop would significantly change the costs, timing, and viability associated with the development of that product candidate.

Research and development activities are central to our business model. We expect research and development costs to increase significantly for the foreseeable future as our development programs progress, including as we continue to progress our clinical trials as well as support preclinical studies for our other research programs.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in executive, finance, investor relations, business development, legal, corporate affairs, information technology, facilities and human resource functions. Other significant costs include corporate facility costs not otherwise included in research and development expenses, legal fees related to intellectual property and corporate matters, and fees for accounting and consulting services.

We anticipate that our general and administrative expenses will increase in the future to support continued research and development activities and potential commercialization of any product candidates we identify and develop. These increases will include increased costs related to the hiring of additional personnel and fees to outside consultants. We also anticipate increased expenses related to reimbursement of third-party patent-related expenses and expenses associated with operating as a public company, including costs for audit, legal, regulatory, and tax-related services, director and officer insurance premiums, and investor relations costs. With respect to reimbursement of third-party intellectual property-related expenses specifically, given the ongoing nature of the opposition and interference proceedings involving the patents licensed to us under our license agreement with The Broad Institute, Inc. and the President and Fellows of Harvard College, we anticipate general and administrative expenses will continue to be significant.

Other Income, Net

For the three months ended March 31, 2023 and 2022, other income, net consisted primarily of interest income, partially offset by accretion of discounts associated with other marketable securities.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of our condensed consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, will be reflected in the condensed consolidated financial statements prospectively from the date of change in estimates.

There have been no material changes to our critical accounting policies from those described in Part II, “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates” in the Annual Report.

Table of Contents

Results of Operations

Comparison of the Three Months ended March 31, 2023 and 2022

The following table summarizes our results of operations for the three months ended March 31, 2023 and 2022, together with the changes in those items in dollars (in thousands) and the respective percentages of change:


	Three Months Ended
	March 31,
	2023		2022		Dollar Change		Percentage Change
Collaboration and other research and development revenues	$	9,851	$	6,771	$	3,080	45	%
Operating expenses:
Research and development		37,804		37,976		(172)	(0)	%
General and administrative		23,008		19,545		3,463	18	%
Total operating expenses		60,812		57,521		3,291	6	%
Other income, net:
Other expense, net		(1,584)		(234)		(1,350)	n/m
Interest income, net		3,509		469		3,040	n/m
Total other income, net		1,925		235		1,690	n/m	%
Net loss	$	(49,036)	$	(50,515)	$	1,479	(3)	%

For our results of operations, we have included the respective percentage of changes, unless greater than 100% or less than (100)%, in which case we have denoted such changes as not meaningful (n/m).

Collaboration and other research and development revenues

Collaboration and other research and development revenues increased by $3.1 million, to $9.9 million for the three months ended March 31, 2023, compared to $6.8 million for three months ended March 31, 2022. This increase is related to the sale of our wholly owned oncology assets and related licenses in January 2023.

Research and development expenses

Research and development expenses remained flat at $37.8 million for the three months ended March 31, 2023 compared to $38.0 million for the same period in 2022. The following table summarizes our research and development expenses for the three months ended March 31, 2023 and 2022, together with the changes in those items in dollars (in thousands) and the respective percentages of change:


	Three Months Ended
	March 31,
	2023		2022		Dollar Change		Percentage Change
Employee related expenses	$	13,459	$	11,994	$	1,465	12	%
External research and development expenses		12,401		14,686		(2,285)	(16)	%
Facility expenses		5,681		4,508		1,173	26	%
Other expenses		2,872		2,119		753	36	%
Stock-based compensation expenses		2,086		3,695		(1,609)	(44)	%
Sublicense and license fees		1,305		974		331	34	%
Total research and development expenses	$	37,804	$	37,976	$	(172)	(0)	%

Table of Contents

The slight decrease in research and development expenses for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 was primarily attributable to:

●

approximately $2.3 million in decreased external research and development expenses related to our reprioritization and targeted focus on our EDIT-301 program and;

●

approximately $1.6 million in decreased stock-based compensation expenses due primarily to a reduction in the market price of our common stock, resulting in a lower valuation of equity awards granted in the three months ended March 31, 2023.

These decreases were offset by:

●

approximately $1.5 million in increased employee-related expenses due to payments in connection with our reprioritization and related reduction in workforce;

●

approximately $1.2 million in increased facility related expenses primarily related to increased lab and manufacturing space; and

●

approximately $0.8 million in increased other expenses related to increased consulting expenses.

General and administrative expenses

General and administrative expenses increased by $3.5 million to $23.0 million for the three months ended March 31, 2023 compared to $19.5 million for the three months ended March 31, 2022. The following table summarizes our general and administrative expenses for the three months ended March 31, 2023 and 2022, together with the changes in those items in dollars (in thousands) and the respective percentages of change:


	Three Months Ended
	March 31,
	2023		2022		Dollar Change		Percentage Change
Professional service expenses	$	9,002	$	1,948	$	7,054	n/m	%
Intellectual property and patent related fees		5,032		3,467		1,565	45	%
Employee related expenses		4,127		4,125		2	0	%
Facility and other expenses		2,426		2,269		157	7	%
Stock-based compensation expenses		2,421		7,736		(5,315)	(69)	%
Total general and administrative expenses	$	23,008	$	19,545	$	3,463	18	%

The increase in general and administrative expenses for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 was primarily attributable to:

●

approximately $7.1 million in increased professional service expenses to support business development activities;

●

approximately $1.6 million in increased intellectual property and patent related fees related to the prosecution and maintenance of our patents; and

●

approximately $0.2 million in increased employee related expenses and facility and other expenses.

These increases were partially offset by approximately $5.3 million in decreased stock-based compensation expense primarily related to performance awards granted in 2021 to our former Chief Executive Officer that were achieved or deemed probable in the first quarter of 2022, for which there was no similar expense in the first quarter of 2023.

Table of Contents

Other income, net

For the three months ended March 31, 2023, other income, net was $1.9 million, which was primarily attributable to interest income, partially offset by accretion of discounts associated with other marketable securities.

For the three months ended March 31, 2022, other income, net was $0.2 million, which was primarily attributable to interest income, partially offset by accretion of discounts associated with other marketable securities.

Liquidity and Capital Resources

Sources of Liquidity

As of March 31, 2023, we have raised an aggregate of $898.0 million in net proceeds through the sale of shares of our common stock in public offerings and at-the-market offerings. We also have funded our business from payments received under our research collaboration with BMS and our strategic alliance with Allergan, which was terminated in August 2020. As of March 31, 2023, we had cash, cash equivalents and marketable securities of $401.8 million.

In May 2021, we entered into a common stock sales agreement with Cowen and Company, LLC (“Cowen”), under which we from time to time can issue and sell shares of our common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million (the “ATM Facility”). As of March 31, 2023, we have not sold any shares of our common stock under the ATM Facility.

In addition to our existing cash, cash equivalents and marketable securities, we are eligible to earn milestone and other payments under our collaboration agreement with BMS. Our ability to earn the milestone payments and the timing of earning these amounts are dependent upon the timing and outcome of our development, regulatory and commercial activities and, as such, are uncertain at this time. As of March 31, 2023, our right to contingent payments under our collaboration agreement with BMS is our only significant committed potential external source of funds.

Cash Flows

The following table provides information regarding our cash flows for the three months ended March 31, 2023 and 2022 (in thousands):


	Three Months Ended
	March 31,
	2023		2022
Net cash (used in) provided by:
Operating activities	$	(35,768)	$	(49,227)
Investing activities		23,267		56,371
Financing activities		—		218
Net (decrease) increase in cash, cash equivalents, and restricted cash	$	(12,501)	$	7,362

Net Cash Used in Operating Activities

The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital.

Net cash used in operating activities was approximately $35.8 million for the three months ended March 31, 2023, which primarily consisted of operating expenses that related to increasing our research efforts, progressing our EDIT-301 program, and supporting business operations.

Table of Contents

Net cash used in operating activities was approximately $49.2 million for the three months ended March 31, 2022, which primarily consisted of operating expenses that related to preclinical and clinical activities, patent costs and license fees, and increased costs as a result of staffing needs.

Net Cash Provided by Investing Activities

Net cash provided by investing activities was approximately $23.3 million for the three months ended March 31, 2023, primarily related to proceeds from maturities of marketable securities of $65.9 million, partially offset by costs used to acquire marketable securities of $40.8 million and purchases of property and equipment of $1.8 million.

Net cash provided by investing activities was approximately $56.4 million for the three months ended March 31, 2022, primarily related to proceeds from maturities of marketable securities of $119.0 million, partially offset by costs used to acquire marketable securities of $60.4 million.

Net Cash Provided by Financing Activities

No cash was provided by or used in financing activities for the three months ended March 31, 2023.

Net cash provided by financing activities was approximately $0.2 million for the three months ended March 31, 2022 primarily related to proceeds received from exercises of options for our common stock.

Funding Requirements

We expect our expenses to increase in connection with our ongoing activities, particularly as we progress the clinical development of EDIT-301; further advance our research programs and our preclinical development activities; seek to identify product candidates and additional research programs; initiate preclinical testing and clinical trials for other product candidates we identify and develop; maintain, expand, and protect our intellectual property portfolio, including reimbursing our licensors for expenses related to the intellectual property that we in-license from such licensors; hire additional clinical, quality control, and scientific personnel; and incur costs associated with operating as a public company. In addition, if we obtain marketing approval for any product candidate that we identify and develop, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, and distribution are not the responsibility of a collaborator. We do not expect to generate significant recurring revenue unless and until we obtain regulatory approval for and commercialize a product candidate. Furthermore, since 2016 we have incurred, and in future years we expect to continue to incur significant costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.

We expect that our existing cash, cash equivalents and marketable securities at March 31, 2023 will enable us to fund our operating expenses and capital expenditure requirements into 2025. Our forecast of the period of time through which our existing cash, cash equivalents and investments will be adequate to support our operations is a forward-looking statement and involves significant risks and uncertainties. We have based this forecast on assumptions that may prove to be wrong, and actual results could vary materially from our expectations, which may adversely affect our capital resources and liquidity. We could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:

●

the scope, progress, results, and costs of drug discovery, preclinical development, laboratory testing, and clinical or natural history study trials for the product candidates we develop;

●

the costs of progressing the clinical development of EDIT-301 to treat SCD and TDT;

●

the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our

Table of Contents

intellectual property and proprietary rights, and defending intellectual property-related claims;

●

the costs, timing, and outcome of regulatory review of the product candidates we develop;

●

the costs of future activities, including product sales, medical affairs, marketing, manufacturing, and distribution, for any product candidates for which we receive regulatory approval;

●

the success of our collaboration with BMS;

●

whether BMS exercises any of its options to extend the research program term and/or to additional research programs under our collaboration;

●

our ability to establish and maintain additional collaborations on favorable terms, if at all;

●

the extent to which we acquire or in-license other medicines and technologies;

●

the costs of reimbursing our licensors for the prosecution and maintenance of the patent rights in-licensed by us; and

●

the costs of operating as a public company.

Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive, and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, any product candidate that we identify and develop, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of genomic medicines that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders’ ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.

If we raise funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Contractual Obligations

As of March 31, 2023, we had non-cancelable operating leases with future minimum lease payments for a total of $46.1 million, of which $8.2 million will be payable in 2023. These minimum lease payments exclude our share of the facility operating expenses, real-estate taxes and other costs that are reimbursable to the landlord under the leases.

Our agreements with certain institutions to license intellectual property include potential milestone payments and success fees, sublicense fees, royalty fees, licensing maintenance fees, and reimbursement of patent maintenance costs that we may be required to pay. Our agreements to license intellectual property include potential milestone

Table of Contents

payments that are dependent upon the development of products using the intellectual property licensed under the agreements and contingent upon the achievement of development or regulatory approval milestones, as well as commercial milestones. These potential obligations are contingent upon future events and the timing and likelihood of such potential obligations are not known with certainty. For further information regarding these agreements, please see Part I, “Item 1. Business—Our Collaborations and Licensing Strategy” in the Annual Report.

We also enter into contracts in the normal course of business with contract research organizations, contract manufacturing organizations and other vendors to assist in the performance of our research and development activities and other services and products for operating purposes. These contracts generally provide for termination at any time upon prior notice.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risk related to changes in interest rates. As of March 31, 2023, we had cash and cash equivalents of $129.0 million, primarily held in money market mutual funds, and marketable securities of $272.8 million, primarily consisting of U.S. government-backed securities, commercial paper and corporate debt securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents, are in the form, or may be in the form of, money market funds or marketable securities and are or may be invested in U.S. Treasury and U.S. government agency obligations. Due to the short-term maturities and low risk profiles of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our investments.

While we contract with certain vendors and institutions internationally, substantially all of our total liabilities as of March 31, 2023 were denominated in the United States dollar and we believe that we do not have any material exposure to foreign currency exchange rate risk.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business. There can be no assurance that any proceedings that result from these third-party actions will be resolved in our favor. In addition, if they are not resolved in our favor, there can be no assurance that the result will not have a material adverse effect on our business, financial condition, results of operations, or prospects. Certain of our intellectual property rights, including ones licensed to us under our licensing agreements, are subject to, and from time to time may be subject to, priority and validity disputes. For additional information regarding these matters, see Part I, “Item 1A. Risk Factors—Risks Related to Our Intellectual Property” in the Annual Report. Regardless of outcome, litigation or other legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

Item 1A. Risk Factors.

Information set forth in this Quarterly Report on Form 10-Q and in the sections entitled “Summary of Risk Factors” and Part I, “Item 1A. Risk Factors” in the Annual Report, includes risks which could materially affect our business, financial condition, results of operations, or prospects. These risks, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our common stock. Additional risks not currently known to us or that we currently deem to be immaterial may also harm our business.

Item 6. Exhibits

Exhibit Index

Exhibit Number		Description of Exhibit
3.1		Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-37687) filed with the Securities and Exchange Commission on March 14, 2023)
31.1*		Rule 13a-14(a) Certification of Principal Executive Officer
31.2*		Rule 13a-14(a) Certification of Principal Financial Officer
32.1+		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. §1350
101*		The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Operations (unaudited), (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited), (iv) Condensed Consolidated Statements of Stockholders’ Equity (unaudited), (v) Condensed Consolidated Statements of Cash Flows (unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags.
104*		The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in Inline XBRL.

* Filed herewith

+ The certifications furnished in Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed

Table of Contents

“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications are not to be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates them by reference.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	EDITAS MEDICINE, INC.


Dated: May 5, 2023	By:	/s/ Michelle Robertson
		Michelle Robertson
		Chief Financial Officer (Principal Financial Officer)

EX-31.1 2 edit-20230331xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Gilmore O’Neill, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Editas Medicine, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 5, 2023	By:	/s/ Gilmore O’Neill
		Gilmore O’Neill Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 edit-20230331xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Michelle Robertson, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Editas Medicine, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 5, 2023	By:	/s/ Michelle Robertson
		Michelle Robertson Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 edit-20230331xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q of Editas Medicine, Inc. (the “Company”) for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. (section) 1350, as adopted pursuant to (section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of her or his knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 5, 2023	By:	/s/ Gilmore O’Neill
		Gilmore O’Neill
		Chief Executive Officer


Date: May 5, 2023	By:	/s/ Michelle Robertson
		Michelle Robertson
		Chief Financial Officer

EX-101.SCH 5 edit-20230331.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Fair Value Measurements - Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Collaboration and Profit-Sharing Agreements link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Commitments and Contingencies - Licensor Expense Reimbursements (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Collaboration and Profit-Sharing Agreements - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stock-based Compensation - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Net Loss per Share - Anti-dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Collaboration and Profit-Sharing Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 edit-20230331_cal.xml EX-101.CAL EX-101.DEF 7 edit-20230331_def.xml EX-101.DEF EX-101.LAB 8 edit-20230331_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Quarterly Report Document Transition Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Marketable securities Receivables, Net, Current Accounts receivable, Balance at End of Period Accounts receivable, Balance at Beginning of Period Accounts receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Marketable Securities, Noncurrent Marketable securities Noncurrent marketable securities Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Operating Lease, Right-of-Use Asset Right-of-use assets Other Assets, Noncurrent Restricted cash and other non-current assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total accrued expenses Contract with Customer, Liability, Current Deferred revenue, current Operating Lease, Liability, Current Operating lease liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Operating lease liabilities, net of current portion Contract with Customer, Liability, Noncurrent Deferred revenue, net of current portion Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity Preferred Stock, Value, Issued Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding Common Stock, Value, Issued Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 68,993,591 and 68,847,382 shares issued, and 68,993,591 and 68,847,382 shares outstanding at March 31, 2023 and December 31, 2022, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance, end of period Balance, beginning of period Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations Revenue from Contract with Customer, Excluding Assessed Tax Collaboration and other research and development revenues Revenue from Contract with Customer, Product and Service [Extensible List] Revenue type Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Operating loss Nonoperating Income (Expense) [Abstract] Other income, net: Other Nonoperating Income (Expense) Other expense, net Investment Income, Net Interest income, net Nonoperating Income (Expense) Total other income, net Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Earnings Per Share, Basic Net loss per share, basic (in dollars per share) Earnings Per Share, Diluted Net loss per share, diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding, diluted (in shares) Condensed Consolidated Statements of Comprehensive Loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive loss: Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Unrealized gain (loss) on marketable debt securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Condensed Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss Other Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Statement of Stockholders' Equity (Deficit) Shares, Outstanding Balance, end of period (in shares) Balance, beginning of period (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Exercise of stock options (in shares) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Vesting of restricted common stock awards Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Vesting of restricted common stock awards (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation expense Other Comprehensive Income (Loss), Net of Tax Unrealized gain (loss) on marketable debt securities Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flow from operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation expense Depreciation Depreciation Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of fixed assets Other Noncash Income (Expense) Other non-cash items, net Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Amount represents the increase (decrease) in right of use assets. Increase (Decrease) in Right Of Use Assets Right-of-use assets Increase (Decrease) in Other Noncurrent Assets Other non-current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Contract with Customer, Liability Deferred revenue Increase (Decrease) in Right Of Use Liability Operating lease liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flow from investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Marketable Securities Purchases of marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from maturities of marketable securities Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flow from financing activities Proceeds from Stock Options Exercised Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents, and restricted cash, end of period Cash, cash equivalents, and restricted cash, beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash and non-cash activities: Capital Expenditures Incurred but Not yet Paid Fixed asset additions included in accounts payable and accrued expenses Operating Lease, Payments Cash paid in connection with operating lease liabilities Capital Lease Obligations Incurred Remeasurement of operating lease liabilities and right-of-use assets due to lease modification Nature of Business Nature of Operations [Text Block] Nature of Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Cash Equivalents and Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Cash Equivalents and Marketable Securities Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Property and Equipment, net Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies No definition available. Collaboration and Profit-Sharing Agreements Collaborative Arrangement Disclosure [Text Block] Collaboration and Profit-Sharing Agreements Stock-based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-based Compensation Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Cash, Cash Equivalents and Investments [Table Text Block] Schedule of cash equivalents and marketable securities Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of assets measured at fair value on a recurring basis Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Property, Plant and Equipment [Table Text Block] Schedule of property and equipment, net Tabular disclosure of account receivable and contract liabilities. Schedule of Accounts Receivable and Contract Liabilities Table Text Block Schedule of accounts receivable and contract liabilities Tabular disclosure of change in contract with customer asset and liability. Schedule of Change in Contract with Customer Asset and Liability [Table Text Block] Schedule of change in contract assets and contract liabilities Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation expense Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of changes in unvested restricted stock Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of stock option activity Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of anti-dilutive common stock equivalents Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to at market offering. At The Market Offering Subsidiary, Sale of Stock [Line Items] Liquidity Stock Issued During Period, Shares, New Issues Number of common stock issued Represents the amount of proceeds from common stock agreed to be issued or sold under the agreement. Sales Agreement, Amount Of Aggregate Sale Proceeds Of Common Stock Agreed To Be Issued Sales agreement amount of aggregate sale proceeds of common stock agreed to be issued Schedule of Cash and Cash Equivalents [Table] Financial Instrument [Axis] Financial Instruments [Domain] Government agency securities. Money market funds Corporate notes/bonds Commercial paper U.S. Treasuries Restricted Cash and Cash Equivalents Items [Line Items] Cash Equivalents and Marketable Securities Available-for-sale Debt Securities, Amortized Cost Basis Amortized Cost Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Available-for-sale Securities, Debt Securities Fair Value Marketable securities Number of Available for Sale Securities Held in Continuous Unrealized Loss Position Twelve Months or Longer Number of securities in an unrealized loss position for more than 12 months Number of noncurrent marketable securities held. Marketable Securities, Noncurrent, Number of Securities Number of noncurrent securities Debt Securities, Available-for-sale, Realized Gain (Loss) Realized gains (losses) on available-for-sale securities EX-101.PRE 9 edit-20230331_pre.xml EX-101.PRE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2023	Apr. 28, 2023
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Entity File Number	001-37687
Entity Registrant Name	EDITAS MEDICINE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4097528
Entity Address, Address Line One	11 Hurley Street
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02141
City Area Code	617
Local Phone Number	401-9000
Title of 12(b) Security	Common Stock
Trading Symbol	EDIT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		68,995,606
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001650664
Amendment Flag	false

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 129,021	$ 141,522
Marketable securities	189,418	202,752
Accounts receivable	242	5,145
Prepaid expenses and other current assets	5,777	7,335
Total current assets	324,458	356,754
Marketable securities	83,339	93,097
Property and equipment, net	13,211	15,569
Right-of-use assets	36,344	43,648
Restricted cash and other non-current assets	6,753	5,253
Total assets	464,105	514,321
Current liabilities:
Accounts payable	9,047	9,511
Accrued expenses	31,560	31,296
Deferred revenue, current	8,221	8,221
Operating lease liabilities	8,327	11,082
Total current liabilities	57,155	60,110
Operating lease liabilities, net of current portion	28,810	32,864
Deferred revenue, net of current portion	60,667	60,667
Total liabilities	146,632	153,641
Stockholders' equity
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 68,993,591 and 68,847,382 shares issued, and 68,993,591 and 68,847,382 shares outstanding at March 31, 2023 and December 31, 2022, respectively	7	7
Additional paid-in capital	1,446,912	1,442,405
Accumulated other comprehensive loss	(2,279)	(3,601)
Accumulated deficit	(1,127,167)	(1,078,131)
Total stockholders' equity	317,473	360,680
Total liabilities and stockholders' equity	$ 464,105	$ 514,321

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Condensed Consolidated Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	195,000,000	195,000,000
Common stock, shares issued	68,993,591	68,847,382
Common stock, shares outstanding	68,993,591	68,847,382

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Condensed Consolidated Statements of Operations
Collaboration and other research and development revenues	$ 9,851	$ 6,771
Revenue type	us-gaap:ServiceMember	us-gaap:ServiceMember
Operating expenses:
Research and development	$ 37,804	$ 37,976
General and administrative	23,008	19,545
Total operating expenses	60,812	57,521
Operating loss	(50,961)	(50,750)
Other income, net:
Other expense, net	(1,584)	(234)
Interest income, net	3,509	469
Total other income, net	1,925	235
Net loss	$ (49,036)	$ (50,515)
Net loss per share, basic (in dollars per share)	$ (0.71)	$ (0.74)
Net loss per share, diluted (in dollars per share)	$ (0.71)	$ (0.74)
Weighted-average common shares outstanding, basic (in shares)	68,924,180	68,484,978
Weighted-average common shares outstanding, diluted (in shares)	68,924,180	68,484,978

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Condensed Consolidated Statements of Comprehensive Loss
Net loss	$ (49,036)	$ (50,515)
Other comprehensive loss:
Unrealized gain (loss) on marketable debt securities	1,322	(2,016)
Comprehensive loss	$ (47,714)	$ (52,531)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Other Accumulated Deficit	Total
Balance, beginning of period at Dec. 31, 2021	$ 7	$ 1,411,827	$ (493)	$ (857,699)	$ 553,642
Balance, beginning of period (in shares) at Dec. 31, 2021	68,435,257
Statement of Stockholders' Equity (Deficit)
Exercise of stock options		218			218
Exercise of stock options (in shares)	12,573
Vesting of restricted common stock awards (in shares)	154,834
Stock-based compensation expense		11,431			11,431
Unrealized gain (loss) on marketable debt securities			(2,016)		(2,016)
Net loss				(50,515)	(50,515)
Balance, end of period at Mar. 31, 2022	$ 7	1,423,476	(2,509)	(908,214)	512,760
Balance, end of period (in shares) at Mar. 31, 2022	68,602,664
Balance, beginning of period at Dec. 31, 2022	$ 7	1,442,405	(3,601)	(1,078,131)	360,680
Balance, beginning of period (in shares) at Dec. 31, 2022	68,847,382
Statement of Stockholders' Equity (Deficit)
Vesting of restricted common stock awards (in shares)	146,209
Stock-based compensation expense		4,507			4,507
Unrealized gain (loss) on marketable debt securities			1,322		1,322
Net loss				(49,036)	(49,036)
Balance, end of period at Mar. 31, 2023	$ 7	$ 1,446,912	$ (2,279)	$ (1,127,167)	$ 317,473
Balance, end of period (in shares) at Mar. 31, 2023	68,993,591

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flow from operating activities
Net loss	$ (49,036)	$ (50,515)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	4,507	11,431
Depreciation	1,544	1,558
Loss on disposal of fixed assets	1,583
Other non-cash items, net	(693)	234
Changes in operating assets and liabilities:
Accounts receivable	4,903	(1,105)
Prepaid expenses and other current assets	1,558	(99)
Right-of-use assets	7,304	2,716
Other non-current assets	(1,500)	(505)
Accounts payable	(557)	(229)
Accrued expenses	1,427	(3,982)
Deferred revenue		(5,516)
Operating lease liabilities	(6,808)	(3,215)
Net cash used in operating activities	(35,768)	(49,227)
Cash flow from investing activities
Purchases of property and equipment	(1,840)	(2,248)
Purchases of marketable securities	(40,798)	(60,381)
Proceeds from maturities of marketable securities	65,905	119,000
Net cash provided by investing activities	23,267	56,371
Cash flow from financing activities
Proceeds from exercise of stock options		218
Net cash provided by financing activities		218
Net (decrease) increase in cash, cash equivalents, and restricted cash	(12,501)	7,362
Cash, cash equivalents, and restricted cash, beginning of period	145,399	207,396
Cash, cash equivalents, and restricted cash, end of period	132,898	214,758
Supplemental disclosure of cash and non-cash activities:
Fixed asset additions included in accounts payable and accrued expenses	370	199
Cash paid in connection with operating lease liabilities	3,897	$ 3,746
Remeasurement of operating lease liabilities and right-of-use assets due to lease modification	$ (3,781)

XML 17 R8.htm IDEA: XBRL DOCUMENT

Nature of Business

3 Months Ended

Mar. 31, 2023

Nature of Business

Nature of Business

1. Nature of Business

Liquidity

XML 18 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Unaudited Interim Financial Information

Summary of Significant Accounting Policies

XML 19 R10.htm IDEA: XBRL DOCUMENT

Cash Equivalents and Marketable Securities

3 Months Ended

Mar. 31, 2023

Cash Equivalents and Marketable Securities

Cash Equivalents and Marketable Securities

3. Cash Equivalents and Marketable Securities

Cash equivalents and marketable securities consisted of the following at March 31, 2023 (in thousands):


			Allowance		Gross		Gross
	Amortized		for Credit		Unrealized		Unrealized		Fair
March 31, 2023	Cost		Losses		Gains		Losses		Value
Cash equivalents and marketable securities:
Government agency securities	$	176,982	$	—	$	42	$	(1,757)	$	175,267
Money market funds		129,021		—		—		—		129,021
Corporate notes/bonds		55,876		—		24		(477)		55,423
Commercial paper		29,809		—		—		(63)		29,746
U.S. Treasuries		12,369		—		—		(48)		12,321
Total	$	404,057	$	—	$	66	$	(2,345)	$	401,778

Cash equivalents and marketable securities consisted of the following at December 31, 2022 (in thousands):


			Allowance		Gross		Gross
	Amortized		for Credit		Unrealized		Unrealized		Fair
December 31, 2022	Cost		Losses		Gains		Losses		Value
Cash equivalents and marketable securities:
Government agency securities	$	161,902	$	—	$	11	$	(2,556)	$	159,357
Money market funds		141,522		—		—		—		141,522
Corporate notes/bonds		57,575		—		2		(694)		56,883
U.S. Treasuries		50,019		—		3		(229)		49,793
Commercial paper		29,954		—		3		(141)		29,816
Total	$	440,972	$	—	$	19	$	(3,620)	$	437,371

There were no realized gains or losses on available-for-sale securities during the three months ended March 31, 2023 and 2022.

XML 20 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2023

Fair Value Measurements

Fair Value Measurements

4. Fair Value Measurements

Assets measured at fair value on a recurring basis as of March 31, 2023 were as follows (in thousands):


			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
	March 31,		Identical Assets		Inputs		Inputs
Financial Assets	2023		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	129,021	$	129,021	$	—	$	—
Marketable securities:
Government agency securities		175,267		—		175,267		—
Corporate notes/bonds		55,423		—		55,423		—
Commercial paper		29,746		—		29,746		—
U.S. Treasuries		12,321		12,321		—		—
Restricted cash and other non-current assets:
Money market funds		3,877		3,877		—		—
Total financial assets	$	405,655	$	145,219	$	260,436	$	—

Assets measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):


			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
	December 31,		Identical Assets		Inputs		Inputs
Financial Assets	2022		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	141,522	$	141,522	$	—	$	—
Marketable securities:
Government agency securities		159,357		—		159,357		—
Corporate bonds		56,883		—		56,883		—
U.S. Treasuries		49,793		49,793		—		—
Commercial paper		29,816		—		29,816		—
Restricted cash and other non-current assets:
Money market funds		3,877		3,877		—		—
Total financial assets	$	441,248	$	195,192	$	246,056	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R12.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2023

Accrued Expenses

Accrued Expenses

5. Accrued Expenses

Accrued expenses consisted of the following (in thousands):


	As of
	March 31,		December 31,
	2023		2022
External research and development expenses	$	21,761	$	16,452
Employee related expenses		5,956		10,140
Intellectual property and patent related fees		2,168		1,809
Professional service expenses		1,566		1,260
Other expenses		109		1,635
Total accrued expenses	$	31,560	$	31,296

XML 22 R13.htm IDEA: XBRL DOCUMENT

Property and Equipment, net

3 Months Ended

Mar. 31, 2023

Property and Equipment, net

Property and Equipment, net

6. Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):


	As of
	March 31,		December 31,
	2023		2022
Laboratory equipment	$	23,813	$	24,407
Leasehold improvements		9,634		9,761
Computer equipment		875		875
Construction-in-progress		369		1,573
Furniture and office equipment		264		264
Software		215		215
Total property and equipment		35,170		37,095
Less: accumulated depreciation		(21,959)		(21,526)
Property and equipment, net	$	13,211	$	15,569

XML 23 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies

Commitments and Contingencies

7. Commitments and Contingencies

Licensor Expense Reimbursement

XML 24 R15.htm IDEA: XBRL DOCUMENT

Collaboration and Profit-Sharing Agreements

3 Months Ended

Mar. 31, 2023

Collaboration and Profit-Sharing Agreements

Collaboration and Profit-Sharing Agreements

8. Collaboration and Profit-Sharing Agreements

Collaboration Revenue


For the three months ended March 31, 2023	Balance at December 31, 2022		Additions		Deductions		Balance at March 31, 2023
Accounts receivable	$	5,145	$	97	$	(5,000)	$	242
Contract liabilities:
Deferred revenue	$	68,888	$	—	$	—	$	68,888

During the three months ended March 31, 2023, the Company recognized the following collaboration revenue (in thousands):


	Three Months Ended
Revenue recognized in the period from:	March 31, 2023
Amounts included in deferred revenue at the beginning of the period	$	—
Performance obligations satisfied in previous periods	$	—

XML 25 R16.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

3 Months Ended

Mar. 31, 2023

Stock-based Compensation

Stock-based Compensation

9. Stock-based Compensation

Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):




	Three Months Ended
	March 31,
	2023		2022
Research and development	$	2,086	$	3,695
General and administrative		2,421		7,736
Total stock-based compensation expense	$	4,507	$	11,431

Restricted Stock Unit Awards

The following is a summary of restricted stock unit awards activity for the three months ended March 31, 2023:


		Weighted
		Average
		Grant Date
		Fair Value
	Shares	Per Share
Unvested restricted stock unit awards as of December 31, 2022	1,499,070	$	18.70
Issued	884,867	$	8.64
Vested	(146,209)	$	19.52
Forfeited	(248,527)	$	21.97
Unvested restricted stock unit awards as of March 31, 2023	1,989,201	$	13.76

Stock Options

The following is a summary of stock option activity for the three months ended March 31, 2023:


		Weighted Average		Remaining	Aggregate Intrinsic
	Shares	Exercise Price		Contractual Life (years)	Value (in thousands)
Outstanding at December 31, 2022	5,276,148	$	23.99	8.0	$	401,529
Granted	1,209,494	$	8.64
Exercised	—	$	—
Cancelled	(326,434)	$	24.56
Outstanding at March 31, 2023	6,159,208	$	20.95	7.9	$	236,504
Exercisable at March 31, 2023	2,168,910	$	30.18	6.0	$	236,504

As of March 31, 2023, total unrecognized compensation expense related to stock options was $32.6 million, which the Company expects to recognize over a remaining weighted-average period of 3.1 years.

XML 26 R17.htm IDEA: XBRL DOCUMENT

Net Loss per Share

3 Months Ended

Mar. 31, 2023

Net Loss per Share

Net Loss per Share

10. Net Loss per Share

The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:


	Three months ended
	March 31,
	2023	2022
Unvested restricted stock and restricted stock unit awards	1,989,201	1,233,218
Outstanding stock options	6,159,208	3,920,083
Total	8,148,409	5,153,301

XML 27 R18.htm IDEA: XBRL DOCUMENT

Cash Equivalents and Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2023

Cash Equivalents and Marketable Securities

Schedule of cash equivalents and marketable securities

Cash equivalents and marketable securities consisted of the following at March 31, 2023 (in thousands):


			Allowance		Gross		Gross
	Amortized		for Credit		Unrealized		Unrealized		Fair
March 31, 2023	Cost		Losses		Gains		Losses		Value
Cash equivalents and marketable securities:
Government agency securities	$	176,982	$	—	$	42	$	(1,757)	$	175,267
Money market funds		129,021		—		—		—		129,021
Corporate notes/bonds		55,876		—		24		(477)		55,423
Commercial paper		29,809		—		—		(63)		29,746
U.S. Treasuries		12,369		—		—		(48)		12,321
Total	$	404,057	$	—	$	66	$	(2,345)	$	401,778

Cash equivalents and marketable securities consisted of the following at December 31, 2022 (in thousands):


			Allowance		Gross		Gross
	Amortized		for Credit		Unrealized		Unrealized		Fair
December 31, 2022	Cost		Losses		Gains		Losses		Value
Cash equivalents and marketable securities:
Government agency securities	$	161,902	$	—	$	11	$	(2,556)	$	159,357
Money market funds		141,522		—		—		—		141,522
Corporate notes/bonds		57,575		—		2		(694)		56,883
U.S. Treasuries		50,019		—		3		(229)		49,793
Commercial paper		29,954		—		3		(141)		29,816
Total	$	440,972	$	—	$	19	$	(3,620)	$	437,371

XML 28 R19.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2023

Fair Value Measurements

Schedule of assets measured at fair value on a recurring basis

Assets measured at fair value on a recurring basis as of March 31, 2023 were as follows (in thousands):


			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
	March 31,		Identical Assets		Inputs		Inputs
Financial Assets	2023		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	129,021	$	129,021	$	—	$	—
Marketable securities:
Government agency securities		175,267		—		175,267		—
Corporate notes/bonds		55,423		—		55,423		—
Commercial paper		29,746		—		29,746		—
U.S. Treasuries		12,321		12,321		—		—
Restricted cash and other non-current assets:
Money market funds		3,877		3,877		—		—
Total financial assets	$	405,655	$	145,219	$	260,436	$	—

Assets measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):


			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
	December 31,		Identical Assets		Inputs		Inputs
Financial Assets	2022		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	141,522	$	141,522	$	—	$	—
Marketable securities:
Government agency securities		159,357		—		159,357		—
Corporate bonds		56,883		—		56,883		—
U.S. Treasuries		49,793		49,793		—		—
Commercial paper		29,816		—		29,816		—
Restricted cash and other non-current assets:
Money market funds		3,877		3,877		—		—
Total financial assets	$	441,248	$	195,192	$	246,056	$	—

XML 29 R20.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2023

Accrued Expenses

Schedule of accrued expenses

Accrued expenses consisted of the following (in thousands):


	As of
	March 31,		December 31,
	2023		2022
External research and development expenses	$	21,761	$	16,452
Employee related expenses		5,956		10,140
Intellectual property and patent related fees		2,168		1,809
Professional service expenses		1,566		1,260
Other expenses		109		1,635
Total accrued expenses	$	31,560	$	31,296

XML 30 R21.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Tables)

3 Months Ended

Mar. 31, 2023

Property and Equipment, net

Schedule of property and equipment, net

Property and equipment, net consisted of the following (in thousands):


	As of
	March 31,		December 31,
	2023		2022
Laboratory equipment	$	23,813	$	24,407
Leasehold improvements		9,634		9,761
Computer equipment		875		875
Construction-in-progress		369		1,573
Furniture and office equipment		264		264
Software		215		215
Total property and equipment		35,170		37,095
Less: accumulated depreciation		(21,959)		(21,526)
Property and equipment, net	$	13,211	$	15,569

XML 31 R22.htm IDEA: XBRL DOCUMENT

Collaboration and Profit-Sharing Agreements (Tables)

3 Months Ended

Mar. 31, 2023

Collaboration and Profit-Sharing Agreements

Schedule of accounts receivable and contract liabilities

The following table presents changes in the Company’s accounts receivable and contract liabilities for the three months ended March 31, 2023 (in thousands):


For the three months ended March 31, 2023	Balance at December 31, 2022		Additions		Deductions		Balance at March 31, 2023
Accounts receivable	$	5,145	$	97	$	(5,000)	$	242
Contract liabilities:
Deferred revenue	$	68,888	$	—	$	—	$	68,888

Schedule of change in contract assets and contract liabilities

During the three months ended March 31, 2023, the Company recognized the following collaboration revenue (in thousands):


	Three Months Ended
Revenue recognized in the period from:	March 31, 2023
Amounts included in deferred revenue at the beginning of the period	$	—
Performance obligations satisfied in previous periods	$	—

XML 32 R23.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2023

Stock-based Compensation

Schedule of stock-based compensation expense

Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):




	Three Months Ended
	March 31,
	2023		2022
Research and development	$	2,086	$	3,695
General and administrative		2,421		7,736
Total stock-based compensation expense	$	4,507	$	11,431

Schedule of changes in unvested restricted stock

The following is a summary of restricted stock unit awards activity for the three months ended March 31, 2023:


		Weighted
		Average
		Grant Date
		Fair Value
	Shares	Per Share
Unvested restricted stock unit awards as of December 31, 2022	1,499,070	$	18.70
Issued	884,867	$	8.64
Vested	(146,209)	$	19.52
Forfeited	(248,527)	$	21.97
Unvested restricted stock unit awards as of March 31, 2023	1,989,201	$	13.76

Schedule of stock option activity

The following is a summary of stock option activity for the three months ended March 31, 2023:


		Weighted Average		Remaining	Aggregate Intrinsic
	Shares	Exercise Price		Contractual Life (years)	Value (in thousands)
Outstanding at December 31, 2022	5,276,148	$	23.99	8.0	$	401,529
Granted	1,209,494	$	8.64
Exercised	—	$	—
Cancelled	(326,434)	$	24.56
Outstanding at March 31, 2023	6,159,208	$	20.95	7.9	$	236,504
Exercisable at March 31, 2023	2,168,910	$	30.18	6.0	$	236,504

XML 33 R24.htm IDEA: XBRL DOCUMENT

Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2023

Net Loss per Share

Schedule of anti-dilutive common stock equivalents

The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:


	Three months ended
	March 31,
	2023	2022
Unvested restricted stock and restricted stock unit awards	1,989,201	1,233,218
Outstanding stock options	6,159,208	3,920,083
Total	8,148,409	5,153,301

XML 34 R25.htm IDEA: XBRL DOCUMENT

Nature of Business (Details) - USD ($) $ in Thousands	3 Months Ended
Nature of Business (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	May 31, 2021
Liquidity
Accumulated deficit	$ 1,127,167	$ 1,078,131
At The Market Offering
Liquidity
Number of common stock issued	0
Sales agreement amount of aggregate sale proceeds of common stock agreed to be issued			$ 300,000

XML 35 R26.htm IDEA: XBRL DOCUMENT

Cash Equivalents and Marketable Securities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) security	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Cash Equivalents and Marketable Securities
Amortized Cost	$ 404,057		$ 440,972
Gross Unrealized Gains	66		19
Gross Unrealized Losses	(2,345)		(3,620)
Fair Value	$ 401,778		437,371
Number of securities in an unrealized loss position for more than 12 months \| security	0
Number of noncurrent securities \| security	56
Noncurrent marketable securities	$ 83,339		93,097
Realized gains (losses) on available-for-sale securities	0	$ 0
Government agency securities.
Cash Equivalents and Marketable Securities
Amortized Cost	176,982		161,902
Gross Unrealized Gains	42		11
Gross Unrealized Losses	(1,757)		(2,556)
Fair Value	175,267		159,357
Money market funds
Cash Equivalents and Marketable Securities
Amortized Cost	129,021		141,522
Fair Value	129,021		141,522
Corporate notes/bonds
Cash Equivalents and Marketable Securities
Amortized Cost	55,876		57,575
Gross Unrealized Gains	24		2
Gross Unrealized Losses	(477)		(694)
Fair Value	55,423		56,883
Commercial paper
Cash Equivalents and Marketable Securities
Amortized Cost	29,809		29,954
Gross Unrealized Gains			3
Gross Unrealized Losses	(63)		(141)
Fair Value	29,746		29,816
U.S. Treasuries
Cash Equivalents and Marketable Securities
Amortized Cost	12,369		50,019
Gross Unrealized Gains			3
Gross Unrealized Losses	(48)		(229)
Fair Value	$ 12,321		$ 49,793

XML 36 R27.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Financial Assets
Marketable securities	$ 401,778	$ 437,371
Money market funds
Financial Assets
Restricted Cash and Cash Equivalents, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent
Corporate notes/bonds
Financial Assets
Marketable securities	$ 55,423	$ 56,883
U.S. Treasuries
Financial Assets
Marketable securities	12,321	49,793
Commercial paper
Financial Assets
Marketable securities	$ 29,746	$ 29,816
Level 1 \| Money market funds
Financial Assets
Restricted Cash and Cash Equivalents, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent
Recurring
Financial Assets
Total financial assets	$ 405,655	$ 441,248
Recurring \| Money market funds
Financial Assets
Cash and cash equivalents	129,021	141,522
Restricted cash	3,877	3,877
Recurring \| Government agency securities
Financial Assets
Marketable securities	175,267	159,357
Recurring \| Corporate notes/bonds
Financial Assets
Marketable securities	55,423	56,883
Recurring \| U.S. Treasuries
Financial Assets
Marketable securities	12,321	49,793
Recurring \| Commercial paper
Financial Assets
Marketable securities	29,746	29,816
Recurring \| Level 1
Financial Assets
Total financial assets	145,219	195,192
Recurring \| Level 1 \| Money market funds
Financial Assets
Cash and cash equivalents	129,021	141,522
Restricted cash	3,877	3,877
Recurring \| Level 1 \| U.S. Treasuries
Financial Assets
Marketable securities	12,321	49,793
Recurring \| Level 2
Financial Assets
Total financial assets	260,436	246,056
Recurring \| Level 2 \| Government agency securities
Financial Assets
Marketable securities	175,267	159,357
Recurring \| Level 2 \| Corporate notes/bonds
Financial Assets
Marketable securities	55,423	56,883
Recurring \| Level 2 \| Commercial paper
Financial Assets
Marketable securities	$ 29,746	$ 29,816

XML 37 R28.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accrued Expenses
External research and development expenses	$ 21,761	$ 16,452
Employee related expenses	5,956	10,140
Intellectual property and patent related fees	2,168	1,809
Professional service expenses	1,566	1,260
Other expenses	109	1,635
Total accrued expenses	$ 31,560	$ 31,296

XML 38 R29.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property and equipment, net
Total property and equipment	$ 35,170	$ 37,095
Less: accumulated depreciation	(21,959)	(21,526)
Property and equipment, net	13,211	15,569
Laboratory equipment
Property and equipment, net
Total property and equipment	23,813	24,407
Leasehold improvements
Property and equipment, net
Total property and equipment	9,634	9,761
Construction-in-progress
Property and equipment, net
Total property and equipment	369	1,573
Computer equipment
Property and equipment, net
Total property and equipment	875	875
Furniture and office equipment
Property and equipment, net
Total property and equipment	264	264
Software
Property and equipment, net
Total property and equipment	$ 215	$ 215

XML 39 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Licensor Expense Reimbursements (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Licensor Expense Reimbursements
Commitments and contingencies
Expense for prosecution and maintenance of patent rights	$ 3.0	$ 2.1

XML 40 R31.htm IDEA: XBRL DOCUMENT

Collaboration and Profit-Sharing Agreements - Revenue Recognition (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Accounts receivable
Accounts receivable, Balance at Beginning of Period	$ 5,145
Accounts Receivable, Additions	97
Accounts Receivable, Deductions	(5,000)
Accounts receivable, Balance at End of Period	242
Contract liabilities:
Deferred Revenue, Balance at Beginning of Period	68,888
Deferred Revenue, Balance at End of Period	$ 68,888

XML 41 R32.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-based compensation disclosures
Compensation expense	$ 4,507	$ 11,431
Research and development
Stock-based compensation disclosures
Compensation expense	2,086	3,695
General and administrative
Stock-based compensation disclosures
Compensation expense	$ 2,421	$ 7,736

XML 42 R33.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Restricted Stock and Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Restricted Stock Units (RSUs)
Changes in unvested restricted stock
Unvested restricted shares, beginning of period (in shares)	1,499,070
Issued (in shares)	884,867
Vested (in shares)	(146,209)
Forfeited (in shares)	(248,527)
Unvested restricted shares, end of period(in shares)	1,989,201	1,499,070
Weighted Average Grant Date Fair Value
Balance, beginning of period	$ 18.70
Issued (in dollars per share)	8.64
Vested (in dollars per share)	19.52
Forfeited (in dollars per share)	21.97
Balance, ending of period	$ 13.76	$ 18.70
Unrecognized stock-based compensation expense	$ 15,400
Period for recognition	2 years 10 months 6 days
Performance based awards \| Employees
Changes in unvested restricted stock
Issued (in shares)	253,100
Stock options
Weighted Average Grant Date Fair Value
Unrecognized stock-based compensation expense	$ 32,600
Period for recognition	3 years 1 month 6 days
Changes in unvested stock options
Outstanding, beginning of period (in shares)	5,276,148
Granted (in shares)	1,209,494
Cancelled (in shares)	(326,434)
Outstanding, end of period (in shares)	6,159,208	5,276,148
Exercisable (in shares)	2,168,910
Outstanding, beginning of period (in dollars per share)	$ 23.99
Granted (in dollars per share)	8.64
Cancelled (in dollars per share)	24.56
Outstanding, end of period (in dollars per share)	20.95	$ 23.99
Exercisable (in dollar per share)	$ 30.18
Remaining contractual life	7 years 10 months 24 days	8 years
Exercisable, remaining contractual life	6 years
Aggregate intrinsic value	$ 236,504	$ 401,529
Exercisable, aggregated intrinsic value	$ 236,504

XML 43 R34.htm IDEA: XBRL DOCUMENT

Net Loss per Share - Anti-dilutive (Details) - shares	3 Months Ended
Net Loss per Share - Anti-dilutive (Details) - shares	Mar. 31, 2023	Mar. 31, 2022
Potentially dilutive securities
Anti-dilutive common stock equivalent shares	8,148,409	5,153,301
Restricted Stock
Potentially dilutive securities
Anti-dilutive common stock equivalent shares	1,989,201	1,233,218
Stock options
Potentially dilutive securities
Anti-dilutive common stock equivalent shares	6,159,208	3,920,083

XML 44 edit-20230331x10q_htm.xml IDEA: XBRL DOCUMENT 0001650664 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001650664 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001650664 edit:AtMarketOfferingMember 2023-01-01 2023-03-31 0001650664 us-gaap:RetainedEarningsMember 2023-03-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001650664 us-gaap:RetainedEarningsMember 2022-12-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001650664 us-gaap:RetainedEarningsMember 2022-03-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001650664 us-gaap:RetainedEarningsMember 2021-12-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001650664 us-gaap:CommonStockMember 2023-03-31 0001650664 us-gaap:CommonStockMember 2022-12-31 0001650664 us-gaap:CommonStockMember 2022-03-31 0001650664 us-gaap:CommonStockMember 2021-12-31 0001650664 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001650664 us-gaap:EmployeeStockOptionMember 2022-12-31 0001650664 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001650664 us-gaap:PerformanceSharesMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-01-01 2023-03-31 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-03-31 0001650664 us-gaap:MoneyMarketFundsMember 2023-03-31 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001650664 us-gaap:MoneyMarketFundsMember 2022-12-31 0001650664 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-03-31 0001650664 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001650664 us-gaap:FurnitureAndFixturesMember 2023-03-31 0001650664 us-gaap:ConstructionInProgressMember 2023-03-31 0001650664 us-gaap:ComputerEquipmentMember 2023-03-31 0001650664 edit:LaboratoryEquipmentMember 2023-03-31 0001650664 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-12-31 0001650664 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001650664 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001650664 us-gaap:ConstructionInProgressMember 2022-12-31 0001650664 us-gaap:ComputerEquipmentMember 2022-12-31 0001650664 edit:LaboratoryEquipmentMember 2022-12-31 0001650664 edit:CommitmentToReimburseLicensorMember 2023-01-01 2023-03-31 0001650664 edit:CommitmentToReimburseLicensorMember 2022-01-01 2022-03-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001650664 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001650664 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001650664 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001650664 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001650664 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001650664 us-gaap:EmployeeStockOptionMember 2023-03-31 0001650664 2022-03-31 0001650664 2021-12-31 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-03-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-03-31 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001650664 us-gaap:MoneyMarketFundsMember 2023-03-31 0001650664 us-gaap:MoneyMarketFundsMember 2022-12-31 0001650664 us-gaap:USTreasurySecuritiesMember 2023-03-31 0001650664 us-gaap:CommercialPaperMember 2023-03-31 0001650664 us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-03-31 0001650664 us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0001650664 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001650664 us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-12-31 0001650664 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001650664 us-gaap:CommercialPaperMember 2022-12-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001650664 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001650664 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001650664 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001650664 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001650664 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001650664 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001650664 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001650664 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001650664 edit:AtMarketOfferingMember 2021-05-31 0001650664 2022-01-01 2022-03-31 0001650664 2023-03-31 0001650664 2022-12-31 0001650664 2023-04-28 0001650664 2023-01-01 2023-03-31 shares iso4217:USD edit:security iso4217:USD shares

http://fasb.org/us-gaap/2022#ServiceMember

68924180

68484978

http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent

0001650664 false --12-31 2023 Q1

http://fasb.org/us-gaap/2022#ServiceMember

-0.71

-0.74

10-Q true 2023-03-31 false 001-37687 EDITAS MEDICINE, INC. DE 46-4097528 11 Hurley Street Cambridge MA 02141 617 401-9000 Common Stock EDIT NASDAQ Yes Yes Large Accelerated Filer false false false 68995606

129021000

141522000

189418000

202752000

242000

5145000

5777000

7335000

324458000

356754000

83339000

93097000

13211000

15569000

36344000

43648000

6753000

5253000

464105000

514321000

9047000

9511000

31560000

31296000

8221000

8327000

11082000

57155000

60110000

28810000

32864000

60667000

146632000

153641000

0.0001

5000000

0.0001

195000000

68993591

68847382

68993591

68847382

7000

1446912000

1442405000

-2279000

-3601000

-1127167000

-1078131000

317473000

360680000

464105000

514321000

9851000

6771000

37804000

37976000

23008000

19545000

60812000

57521000

-50961000

-50750000

-1584000

-234000

3509000

469000

1925000

235000

-49036000

-50515000

-0.71

-0.74

68924180

68484978

-49036000

-50515000

1322000

-2016000

-47714000

-52531000

68847382

7000

1442405000

-3601000

-1078131000

360680000

146209

4507000

1322000

-49036000

68993591

7000

1446912000

-2279000

-1127167000

317473000

68435257

7000

1411827000

-493000

-857699000

553642000

12573

218000

154834

11431000

-2016000

-50515000

68602664

7000

1423476000

-2509000

-908214000

512760000

-49036000

-50515000

4507000

11431000

1544000

1558000

-1583000

693000

-234000

-4903000

1105000

-1558000

99000

-7304000 -2716000

1500000

505000

-557000

-229000

1427000

-3982000

-5516000

-6808000

-3215000

-35768000

-49227000

1840000

2248000

40798000

60381000

65905000

119000000

23267000

56371000

218000

-12501000

7362000

145399000

207396000

132898000

214758000

370000

199000

3897000

3746000

3781000

1. Nature of BusinessEditas Medicine, Inc. (the “Company”) is a clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc., a wholly-owned subsidiary of the Bristol-Myers Squibb Company (“BMS”), and payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, which was terminated in August 2020. The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.LiquidityIn May 2021, the Company entered into a common stock sales agreement with Cowen and Company, LLC (“Cowen”), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million (the “ATM Facility”). As of March 31, 2023, the Company has not sold any shares of its common stock under the ATM Facility. The Company has incurred annual net operating losses in every year since its inception. The Company expects that its existing cash, cash equivalents and marketable securities at March 31, 2023 will enable it to fund its operating expenses and capital expenditure requirements into 2025. The Company had an accumulated deficit of $1.1 billion at March 31, 2023, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.

300000000.0

-1100000000

2. Summary of Significant Accounting PoliciesUnaudited Interim Financial InformationThe condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”).The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Editas Securities Corporation and Editas Medicine, LLC. All intercompany transactions and balances of the subsidiaries have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended March 31, 2023 and 2022 are referred to as the first quarter of 2023 and 2022, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.Summary of Significant Accounting PoliciesThe Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” to the consolidated financial statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report.

3. Cash Equivalents and Marketable Securities Cash equivalents and marketable securities consisted of the following at March 31, 2023 (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">Allowance</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;">Amortized</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">for Credit</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.7%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents and marketable securities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;">Government agency securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> 176,982</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> 42</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> (1,757)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 175,267</td></tr><tr><td style="vertical-align:bottom;width:36.7%;background:#cceeff;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"> 129,021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 129,021</td></tr><tr><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;">Corporate notes/bonds</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> 55,876</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> 24</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> (477)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 55,423</td></tr><tr><td style="vertical-align:bottom;width:36.7%;background:#cceeff;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"> 29,809</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> (63)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 29,746</td></tr><tr><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;">U.S. Treasuries</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,369</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (48)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,321</td></tr><tr><td style="vertical-align:bottom;width:36.7%;background:#cceeff;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 404,057</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 66</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2,345)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 401,778</td></tr></table> Cash equivalents and marketable securities consisted of the following at December 31, 2022 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;">Allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;">Amortized</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;">for Credit </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;width:40.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;width:40.93%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents and marketable securities:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;">Government agency securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 161,902</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> 11</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"> (2,556)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"> 159,357</td></tr><tr><td style="vertical-align:bottom;width:40.93%;background:#cceeff;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 141,522</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"> 141,522</td></tr><tr><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;">Corporate notes/bonds</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 57,575</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> 2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"> (694)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"> 56,883</td></tr><tr><td style="vertical-align:bottom;width:40.93%;background:#cceeff;margin:0pt;padding:0pt;">U.S. Treasuries</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 50,019</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 3</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"> (229)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"> 49,793</td></tr><tr><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,954</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (141)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,816</td></tr><tr><td style="vertical-align:bottom;width:40.93%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 440,972</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 19</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (3,620)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 437,371</td></tr></table>As of March 31, 2023, the Company did not hold any marketable securities that had been in an unrealized loss position for more than twelve months. Furthermore, the Company has determined that there were no material changes in the credit risk of the debt securities. As of March 31, 2023, the Company holds 56 securities with an aggregate fair value of $83.3 million that had remaining maturities greater than one year.There were no realized gains or losses on available-for-sale securities during the three months ended March 31, 2023 and 2022.

Cash equivalents and marketable securities consisted of the following at March 31, 2023 (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">Allowance</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;">Amortized</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">for Credit</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.7%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents and marketable securities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;">Government agency securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> 176,982</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> 42</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> (1,757)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 175,267</td></tr><tr><td style="vertical-align:bottom;width:36.7%;background:#cceeff;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"> 129,021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 129,021</td></tr><tr><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;">Corporate notes/bonds</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> 55,876</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> 24</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"> (477)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 55,423</td></tr><tr><td style="vertical-align:bottom;width:36.7%;background:#cceeff;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"> 29,809</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> (63)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 29,746</td></tr><tr><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;">U.S. Treasuries</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,369</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (48)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,321</td></tr><tr><td style="vertical-align:bottom;width:36.7%;background:#cceeff;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 404,057</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 66</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2,345)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 401,778</td></tr></table> Cash equivalents and marketable securities consisted of the following at December 31, 2022 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;">Allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;">Amortized</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;">for Credit </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;width:40.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;width:40.93%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents and marketable securities:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;">Government agency securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 161,902</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> 11</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"> (2,556)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"> 159,357</td></tr><tr><td style="vertical-align:bottom;width:40.93%;background:#cceeff;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 141,522</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"> 141,522</td></tr><tr><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;">Corporate notes/bonds</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 57,575</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> 2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"> (694)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"> 56,883</td></tr><tr><td style="vertical-align:bottom;width:40.93%;background:#cceeff;margin:0pt;padding:0pt;">U.S. Treasuries</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 50,019</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 3</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"> (229)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"> 49,793</td></tr><tr><td style="vertical-align:bottom;width:40.93%;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,954</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (141)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,816</td></tr><tr><td style="vertical-align:bottom;width:40.93%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 440,972</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 19</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (3,620)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 437,371</td></tr></table>

176982000

42000

1757000

175267000

129021000

55876000

24000

477000

55423000

29809000

63000

29746000

12369000

48000

12321000

404057000

66000

2345000

401778000

161902000

11000

2556000

159357000

141522000

57575000

2000

694000

56883000

50019000

3000

229000

49793000

29954000

3000

141000

29816000

440972000

19000

3620000

437371000

83300000

4. Fair Value MeasurementsAssets measured at fair value on a recurring basis as of March 31, 2023 were as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">Quoted Prices</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Significant</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">in Active</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Significant</td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">Markets for</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Observable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Unobservable</td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">Identical Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Inputs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Inputs</td></tr><tr><td style="vertical-align:bottom;width:40.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Financial Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 2)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 3)</td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"> 129,021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> 129,021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;">Marketable securities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;">Government agency securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"> 175,267</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> 175,267</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;">Corporate notes/bonds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"> 55,423</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> 55,423</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"> 29,746</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> 29,746</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;">U.S. Treasuries</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"> 12,321</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> 12,321</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;">Restricted cash and other non-current assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,877</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,877</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;">Total financial assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 405,655</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 145,219</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 260,436</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table>Assets measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Quoted Prices</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Significant</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">in Active</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Significant</td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Markets for</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Observable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Unobservable</td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Identical Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Inputs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Inputs</td></tr><tr><td style="vertical-align:bottom;width:45.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Financial Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 2)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 3)</td></tr><tr><td style="vertical-align:bottom;width:45.75%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 141,522</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 141,522</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;background:#cceeff;margin:0pt;padding:0pt;">Marketable securities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;">Government agency securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 159,357</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 159,357</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;background:#cceeff;margin:0pt;padding:0pt;">Corporate bonds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> 56,883</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> 56,883</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;">U.S. Treasuries</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 49,793</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 49,793</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;background:#cceeff;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> 29,816</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> 29,816</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;">Restricted cash and other non-current assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.75%;background:#cceeff;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,877</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,877</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;">Total financial assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 441,248</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 195,192</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 246,056</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">—</td></tr></table>

Assets measured at fair value on a recurring basis as of March 31, 2023 were as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">Quoted Prices</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Significant</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">in Active</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Significant</td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">Markets for</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Observable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Unobservable</td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">Identical Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Inputs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;">Inputs</td></tr><tr><td style="vertical-align:bottom;width:40.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Financial Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 2)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 3)</td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"> 129,021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> 129,021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;">Marketable securities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;">Government agency securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"> 175,267</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> 175,267</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;">Corporate notes/bonds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"> 55,423</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> 55,423</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"> 29,746</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> 29,746</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;">U.S. Treasuries</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"> 12,321</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> 12,321</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;">Restricted cash and other non-current assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,877</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,877</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;">Total financial assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 405,655</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 145,219</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 260,436</td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table>Assets measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Quoted Prices</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Significant</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">in Active</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Significant</td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Markets for</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Observable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Unobservable</td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Identical Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Inputs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;">Inputs</td></tr><tr><td style="vertical-align:bottom;width:45.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Financial Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 2)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 3)</td></tr><tr><td style="vertical-align:bottom;width:45.75%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 141,522</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 141,522</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;background:#cceeff;margin:0pt;padding:0pt;">Marketable securities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;">Government agency securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 159,357</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 159,357</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;background:#cceeff;margin:0pt;padding:0pt;">Corporate bonds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> 56,883</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> 56,883</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;">U.S. Treasuries</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 49,793</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 49,793</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;background:#cceeff;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> 29,816</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> 29,816</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;">Restricted cash and other non-current assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.75%;background:#cceeff;margin:0pt;padding:0pt;">Money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,877</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,877</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;">Total financial assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 441,248</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 195,192</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 246,056</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">—</td></tr></table>

129021000

175267000

55423000

29746000

12321000

3877000

405655000

145219000

260436000

141522000

159357000

56883000

49793000

29816000

3877000

441248000

195192000

246056000

5. Accrued ExpensesAccrued expenses consisted of the following (in thousands):<div style="padding-left:33pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:86.63%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;">External research and development expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"> 21,761</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"> 16,452</td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;">Employee related expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"> 5,956</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"> 10,140</td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;">Intellectual property and patent related fees</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"> 2,168</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"> 1,809</td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;">Professional service expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"> 1,566</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"> 1,260</td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;">Other expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 109</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,635</td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;">Total accrued expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,560</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,296</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"></td></tr></table></div>

Accrued expenses consisted of the following (in thousands):<div style="padding-left:33pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:86.63%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;">External research and development expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"> 21,761</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"> 16,452</td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;">Employee related expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"> 5,956</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"> 10,140</td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;">Intellectual property and patent related fees</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"> 2,168</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"> 1,809</td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;">Professional service expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"> 1,566</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"> 1,260</td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;">Other expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 109</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,635</td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;">Total accrued expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,560</td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,296</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"></td></tr></table></div>

21761000 16452000

5956000

10140000

2168000 1809000

1566000

1260000

109000

1635000

31560000

31296000

6. Property and Equipment, netProperty and equipment, net consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.24%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;">Laboratory equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 23,813</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 24,407</td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;">Leasehold improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 9,634</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> 9,761</td></tr><tr><td style="vertical-align:bottom;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;">Computer equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 875</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 875</td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;">Construction-in-progress</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 369</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> 1,573</td></tr><tr><td style="vertical-align:bottom;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;">Furniture and office equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 264</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 264</td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 215</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 215</td></tr><tr><td style="vertical-align:bottom;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;">Total property and equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 35,170</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 37,095</td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;">Less: accumulated depreciation</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21,959)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21,526)</td></tr><tr><td style="vertical-align:bottom;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;">Property and equipment, net</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,211</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,569</td></tr></table>

Property and equipment, net consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.24%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;">Laboratory equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 23,813</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 24,407</td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;">Leasehold improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 9,634</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> 9,761</td></tr><tr><td style="vertical-align:bottom;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;">Computer equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 875</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 875</td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;">Construction-in-progress</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 369</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> 1,573</td></tr><tr><td style="vertical-align:bottom;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;">Furniture and office equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 264</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 264</td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 215</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 215</td></tr><tr><td style="vertical-align:bottom;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;">Total property and equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 35,170</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 37,095</td></tr><tr><td style="vertical-align:bottom;width:67.19%;margin:0pt;padding:0pt;">Less: accumulated depreciation</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21,959)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21,526)</td></tr><tr><td style="vertical-align:bottom;width:67.19%;background:#cceeff;margin:0pt;padding:0pt;">Property and equipment, net</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,211</td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,569</td></tr></table>

23813000

24407000

9634000

9761000

875000

369000

1573000

264000

215000

35170000

37095000

21959000

21526000

13211000

15569000

7. Commitments and ContingenciesThe Company is a party to a number of license agreements under which the Company licenses patents, patent applications and other intellectual property from third parties. As such, the Company is obligated to pay licensors for various costs including upfront licenses fees, annual license fees, certain licensor expense reimbursements, success payments, research funding payments, and milestones triggerable upon certain development, regulatory, and commercial events as well as royalties on future products. These contracts are generally cancellable, with notice, at the Company’s option and do not have significant cancellation penalties. The terms and conditions as well as the accounting analysis for the Company’s significant commitments and contingencies are described in Note 8, “Commitments and Contingencies” to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.Licensor Expense ReimbursementThe Company is obligated to reimburse The Broad Institute, Inc. (“Broad”) and the President and Fellows of Harvard College (“Harvard”) for expenses incurred by each of them associated with the prosecution and maintenance of the patent rights that the Company licenses from them pursuant to the license agreement by and among the Company, Broad and Harvard, including the interference and opposition proceedings involving patents licensed to the Company under the license agreement, and other license agreements between the Company and Broad. As such, the Company anticipates that it has a substantial commitment in connection with these proceedings until such time as these proceedings have been resolved, but the amount of such commitment is not determinable. The Company incurred an aggregate of $3.0 million and $2.1 million in expense during the three months ended March 31, 2023 and 2022, respectively, for such reimbursement.

3000000.0

2100000

8. Collaboration and Profit-Sharing Agreements The Company has entered into multiple collaborations, out-licenses and strategic alliances with third parties that typically involve payments to or from the Company, including up-front payments, payments for research and development services, option payments, milestone payments and royalty payments to or from the Company. The terms and conditions as well as the accounting analysis for the Company’s significant collaborations, out-licenses and strategic alliances are described in Note 9, “Collaboration and Profit-Sharing Agreements” to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report. Collaboration RevenueAs of March 31, 2023, the Company’s contract liabilities were primarily related to the Company’s collaboration with BMS. The following table presents changes in the Company’s accounts receivable and contract liabilities for the three months ended March 31, 2023 (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.99%;margin:0pt;padding:0pt;">For the three months ended March 31, 2023</td><td colspan="2" style="vertical-align:middle;width:13.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">Balance at December 31, 2022</td><td style="vertical-align:middle;width:1.54%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:12.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">Additions</td><td style="vertical-align:middle;width:1.54%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:12.13%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">Deductions</td><td style="vertical-align:middle;width:1.54%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:12.07%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">Balance at March 31, 2023</td></tr><tr><td style="vertical-align:bottom;width:44.99%;background:#cceeff;margin:0pt;padding:0pt;">Accounts receivable</td><td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 5,145</td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"> 97</td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> (5,000)</td><td style="vertical-align:middle;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 242</td></tr><tr><td style="vertical-align:bottom;width:44.99%;margin:0pt;padding:0pt;">Contract liabilities:</td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:middle;width:44.99%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred revenue</td><td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:middle;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 68,888</td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 68,888</td></tr></table>During the three months ended March 31, 2023, the Company recognized the following collaboration revenue (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:77.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.32%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:77.32%;margin:0pt;padding:0pt;">Revenue recognized in the period from:</td><td colspan="2" style="vertical-align:middle;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2023</td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:77.32%;background:#cceeff;margin:0pt;padding:0pt;">Amounts included in deferred revenue at the beginning of the period</td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:77.32%;margin:0pt;padding:0pt;">Performance obligations satisfied in previous periods</td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;margin:0pt;padding:0pt;"> —</td></tr></table>

The following table presents changes in the Company’s accounts receivable and contract liabilities for the three months ended March 31, 2023 (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.99%;margin:0pt;padding:0pt;">For the three months ended March 31, 2023</td><td colspan="2" style="vertical-align:middle;width:13.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">Balance at December 31, 2022</td><td style="vertical-align:middle;width:1.54%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:12.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">Additions</td><td style="vertical-align:middle;width:1.54%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:12.13%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">Deductions</td><td style="vertical-align:middle;width:1.54%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:12.07%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">Balance at March 31, 2023</td></tr><tr><td style="vertical-align:bottom;width:44.99%;background:#cceeff;margin:0pt;padding:0pt;">Accounts receivable</td><td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 5,145</td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"> 97</td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> (5,000)</td><td style="vertical-align:middle;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 242</td></tr><tr><td style="vertical-align:bottom;width:44.99%;margin:0pt;padding:0pt;">Contract liabilities:</td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:middle;width:44.99%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred revenue</td><td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:middle;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 68,888</td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 68,888</td></tr></table>

5145000

97000 5000000

242000

68888000

During the three months ended March 31, 2023, the Company recognized the following collaboration revenue (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:77.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.32%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:77.32%;margin:0pt;padding:0pt;">Revenue recognized in the period from:</td><td colspan="2" style="vertical-align:middle;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2023</td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:77.32%;background:#cceeff;margin:0pt;padding:0pt;">Amounts included in deferred revenue at the beginning of the period</td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:77.32%;margin:0pt;padding:0pt;">Performance obligations satisfied in previous periods</td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;margin:0pt;padding:0pt;"> —</td></tr></table>

9. Stock-based CompensationTotal compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.24%;margin:0pt;padding:0pt;">Three Months Ended </td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:33.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#cceeff;margin:0pt;padding:0pt;"> 2,086</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"> 3,695</td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,421</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,736</td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;">Total stock-based compensation expense</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,507</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,431</td></tr></table>Restricted Stock Unit AwardsThe following is a summary of restricted stock unit awards activity for the three months ended March 31, 2023:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;">Weighted</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;">Grant Date</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;">Fair Value</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Per Share</td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;">Unvested restricted stock unit awards as of December 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"> 1,499,070</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"> 18.70</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;">Issued</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"> 884,867</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> 8.64</td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;">Vested</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"> (146,209)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"> 19.52</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;">Forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (248,527)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> 21.97</td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;">Unvested restricted stock unit awards as of March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,989,201</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"> 13.76</td></tr></table>The restricted stock units issued in the three months ended March 31, 2023 include 253,100 units granted to certain employees that contain performance-based vesting provisions. The Company recognizes the fair value of the performance-based units through the expected achievement date if the performance-based vesting provisions are deemed probable.As of March 31, 2023, total unrecognized compensation expense related to unvested restricted stock unit awards was $15.4 million, which the Company expects to recognize over a remaining weighted-average period of 2.85 years.Stock OptionsThe following is a summary of stock option activity for the three months ended March 31, 2023:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;">Weighted Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;">Aggregate Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercise Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Contractual Life (years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value (in thousands)</td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;">Outstanding at December 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"> 5,276,148</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"> 23.99</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"> 8.0</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"> 401,529</td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"> 1,209,494</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"> 8.64</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;">Exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;">Cancelled</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (326,434)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"> 24.56</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;">Outstanding at March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,159,208</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"> 20.95</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"> 7.9</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"> 236,504</td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;">Exercisable at March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,168,910</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"> 30.18</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"> 6.0</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"> 236,504</td></tr></table>As of March 31, 2023, total unrecognized compensation expense related to stock options was $32.6 million, which the Company expects to recognize over a remaining weighted-average period of 3.1 years.

Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.24%;margin:0pt;padding:0pt;">Three Months Ended </td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:33.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#cceeff;margin:0pt;padding:0pt;"> 2,086</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"> 3,695</td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,421</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,736</td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;">Total stock-based compensation expense</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,507</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,431</td></tr></table>

2086000

3695000

2421000

7736000

4507000

11431000

The following is a summary of restricted stock unit awards activity for the three months ended March 31, 2023:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;">Weighted</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;">Grant Date</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;">Fair Value</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Per Share</td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;">Unvested restricted stock unit awards as of December 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"> 1,499,070</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"> 18.70</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;">Issued</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"> 884,867</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> 8.64</td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;">Vested</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"> (146,209)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"> 19.52</td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;">Forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (248,527)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> 21.97</td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;">Unvested restricted stock unit awards as of March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,989,201</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"> 13.76</td></tr></table>

1499070

18.70

884867

8.64

146209

19.52

248527

21.97

1989201

13.76

253100

15400000

P2Y10M6D

The following is a summary of stock option activity for the three months ended March 31, 2023:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;">Weighted Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;">Aggregate Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercise Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Contractual Life (years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value (in thousands)</td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;">Outstanding at December 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"> 5,276,148</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"> 23.99</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"> 8.0</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"> 401,529</td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"> 1,209,494</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"> 8.64</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;">Exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;">Cancelled</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (326,434)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"> 24.56</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;">Outstanding at March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,159,208</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"> 20.95</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"> 7.9</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"> 236,504</td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;">Exercisable at March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,168,910</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"> 30.18</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"> 6.0</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"> 236,504</td></tr></table>

5276148

23.99

P8Y

401529000

1209494

8.64

326434

24.56

6159208

20.95

P7Y10M24D

236504000

2168910

30.18

P6Y

236504000

32600000

P3Y1M6D

10. Net Loss per ShareBasic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury stock and if converted methods. Contingently issuable shares are included in the calculation of basic loss per share as of the beginning of the period in which all the necessary conditions have been satisfied. Contingently issuable shares are included in diluted loss per share based on the number of shares, if any, that would be issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, if the results are dilutive. For purposes of the diluted net loss per share calculation, stock options are considered to be common stock equivalents, but they were excluded from the Company’s calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.29%;margin:0pt;padding:0pt;">Three months ended</td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;">Unvested restricted stock and restricted stock unit awards</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"> 1,989,201</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"> 1,233,218</td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;">Outstanding stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,159,208</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,920,083</td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,148,409</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,153,301</td></tr></table>

The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.29%;margin:0pt;padding:0pt;">Three months ended</td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;">Unvested restricted stock and restricted stock unit awards</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"> 1,989,201</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"> 1,233,218</td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;">Outstanding stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,159,208</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,920,083</td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,148,409</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,153,301</td></tr></table>

1989201

1233218

6159208

3920083

8148409

5153301

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 103 177 1 false 30 0 false 4 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 00500 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Nature of Business Sheet http://www.editasmedicine.com/role/DisclosureNatureOfBusiness Nature of Business Notes 8 false false R9.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10301 - Disclosure - Cash Equivalents and Marketable Securities Sheet http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecurities Cash Equivalents and Marketable Securities Notes 10 false false R11.htm 10401 - Disclosure - Fair Value Measurements Sheet http://www.editasmedicine.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 10501 - Disclosure - Accrued Expenses Sheet http://www.editasmedicine.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 12 false false R13.htm 10601 - Disclosure - Property and Equipment, net Sheet http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet Property and Equipment, net Notes 13 false false R14.htm 10701 - Disclosure - Commitments and Contingencies Sheet http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 10801 - Disclosure - Collaboration and Profit-Sharing Agreements Sheet http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreements Collaboration and Profit-Sharing Agreements Notes 15 false false R16.htm 10901 - Disclosure - Stock-based Compensation Sheet http://www.editasmedicine.com/role/DisclosureStockBasedCompensation Stock-based Compensation Notes 16 false false R17.htm 11001 - Disclosure - Net Loss per Share Sheet http://www.editasmedicine.com/role/DisclosureNetLossPerShare Net Loss per Share Notes 17 false false R18.htm 30303 - Disclosure - Cash Equivalents and Marketable Securities (Tables) Sheet http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables Cash Equivalents and Marketable Securities (Tables) Tables http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecurities 18 false false R19.htm 30403 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.editasmedicine.com/role/DisclosureFairValueMeasurements 19 false false R20.htm 30503 - Disclosure - Accrued Expenses (Tables) Sheet http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.editasmedicine.com/role/DisclosureAccruedExpenses 20 false false R21.htm 30603 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, net (Tables) Tables http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet 21 false false R22.htm 30803 - Disclosure - Collaboration and Profit-Sharing Agreements (Tables) Sheet http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsTables Collaboration and Profit-Sharing Agreements (Tables) Tables http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreements 22 false false R23.htm 30903 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.editasmedicine.com/role/DisclosureStockBasedCompensation 23 false false R24.htm 31003 - Disclosure - Net Loss per Share (Tables) Sheet http://www.editasmedicine.com/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.editasmedicine.com/role/DisclosureNetLossPerShare 24 false false R25.htm 40101 - Disclosure - Nature of Business (Details) Sheet http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails Nature of Business (Details) Details http://www.editasmedicine.com/role/DisclosureNatureOfBusiness 25 false false R26.htm 40301 - Disclosure - Cash Equivalents and Marketable Securities (Details) Sheet http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails Cash Equivalents and Marketable Securities (Details) Details http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables 26 false false R27.htm 40401 - Disclosure - Fair Value Measurements - Recurring Basis (Details) Sheet http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails Fair Value Measurements - Recurring Basis (Details) Details 27 false false R28.htm 40501 - Disclosure - Accrued Expenses (Details) Sheet http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables 28 false false R29.htm 40601 - Disclosure - Property and Equipment, net (Details) Sheet http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails Property and Equipment, net (Details) Details http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables 29 false false R30.htm 40701 - Disclosure - Commitments and Contingencies - Licensor Expense Reimbursements (Details) Sheet http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementsDetails Commitments and Contingencies - Licensor Expense Reimbursements (Details) Details 30 false false R31.htm 40801 - Disclosure - Collaboration and Profit-Sharing Agreements - Revenue Recognition (Details) Sheet http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsRevenueRecognitionDetails Collaboration and Profit-Sharing Agreements - Revenue Recognition (Details) Details 31 false false R32.htm 40901 - Disclosure - Stock-based Compensation - Expense (Details) Sheet http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails Stock-based Compensation - Expense (Details) Details 32 false false R33.htm 40902 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details) Sheet http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails Stock-based Compensation - Restricted Stock and Stock Options (Details) Details 33 false false R34.htm 41001 - Disclosure - Net Loss per Share - Anti-dilutive (Details) Sheet http://www.editasmedicine.com/role/DisclosureNetLossPerShareAntiDilutiveDetails Net Loss per Share - Anti-dilutive (Details) Details 34 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:PreferredStockSharesOutstanding, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - edit-20230331x10q.htm 9 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 5 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList, us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList - edit-20230331x10q.htm 9 edit-20230331x10q.htm edit-20230331.xsd edit-20230331_cal.xml edit-20230331_def.xml edit-20230331_lab.xml edit-20230331_pre.xml edit-20230331xex31d1.htm edit-20230331xex31d2.htm edit-20230331xex32d1.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 51 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "edit-20230331x10q.htm": { "axisCustom": 0, "axisStandard": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 361, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 103, "dts": { "calculationLink": { "local": [ "edit-20230331_cal.xml" ] }, "definitionLink": { "local": [ "edit-20230331_def.xml" ] }, "inline": { "local": [ "edit-20230331x10q.htm" ] }, "labelLink": { "local": [ "edit-20230331_lab.xml" ] }, "presentationLink": { "local": [ "edit-20230331_pre.xml" ] }, "schema": { "local": [ "edit-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 283, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 14, "http://xbrl.sec.gov/dei/2022": 5, "total": 19 }, "keyCustom": 9, "keyStandard": 168, "memberCustom": 3, "memberStandard": 25, "nsprefix": "edit", "nsuri": "http://www.editasmedicine.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Cash Equivalents and Marketable Securities", "menuCat": "Notes", "order": "10", "role": "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecurities", "shortName": "Cash Equivalents and Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "11", "role": "http://www.editasmedicine.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Accrued Expenses", "menuCat": "Notes", "order": "12", "role": "http://www.editasmedicine.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Property and Equipment, net", "menuCat": "Notes", "order": "13", "role": "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "14", "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Collaboration and Profit-Sharing Agreements", "menuCat": "Notes", "order": "15", "role": "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreements", "shortName": "Collaboration and Profit-Sharing Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Stock-based Compensation", "menuCat": "Notes", "order": "16", "role": "http://www.editasmedicine.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Net Loss per Share", "menuCat": "Notes", "order": "17", "role": "http://www.editasmedicine.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Cash Equivalents and Marketable Securities (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables", "shortName": "Cash Equivalents and Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "19", "role": "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Accrued Expenses (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Property and Equipment, net (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Collaboration and Profit-Sharing Agreements (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsTables", "shortName": "Collaboration and Profit-Sharing Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Stock-based Compensation (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Net Loss per Share (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.editasmedicine.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Nature of Business (Details)", "menuCat": "Details", "order": "25", "role": "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails", "shortName": "Nature of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarketOfferingMember_j9Hg6t7hhUSyXJ6EsRj2rw", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_XhFnm-7Gfk6dIdJI0yeiFg", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Cash Equivalents and Marketable Securities (Details)", "menuCat": "Details", "order": "26", "role": "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails", "shortName": "Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Fair Value Measurements - Recurring Basis (Details)", "menuCat": "Details", "order": "27", "role": "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails", "shortName": "Fair Value Measurements - Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6ivkxvAuDEyptPn3dkfaHA", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "-3", "first": true, "lang": null, "name": "edit:AccruedExternalResearchAndDevelopmentExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Accrued Expenses (Details)", "menuCat": "Details", "order": "28", "role": "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "-3", "first": true, "lang": null, "name": "edit:AccruedExternalResearchAndDevelopmentExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Property and Equipment, net (Details)", "menuCat": "Details", "order": "29", "role": "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_aFxXXM1pFEqf9d7v1vP3Aw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_WITGpN8dy0OJ3oxYS2XudQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_aFxXXM1pFEqf9d7v1vP3Aw", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_Uw7-rUbabUm0coj3nuD-uw", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfessionalAndContractServicesExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Commitments and Contingencies - Licensor Expense Reimbursements (Details)", "menuCat": "Details", "order": "30", "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementsDetails", "shortName": "Commitments and Contingencies - Licensor Expense Reimbursements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_Uw7-rUbabUm0coj3nuD-uw", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfessionalAndContractServicesExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_I4j-uW1oYUSNmUUzyXrxzg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Collaboration and Profit-Sharing Agreements - Revenue Recognition (Details)", "menuCat": "Details", "order": "31", "role": "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsRevenueRecognitionDetails", "shortName": "Collaboration and Profit-Sharing Agreements - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "-3", "lang": null, "name": "edit:AccountsReceivableAdditions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Stock-based Compensation - Expense (Details)", "menuCat": "Details", "order": "32", "role": "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails", "shortName": "Stock-based Compensation - Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6SWEk03p0EqRmJZhUNVsOw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_XhFnm-7Gfk6dIdJI0yeiFg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details)", "menuCat": "Details", "order": "33", "role": "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails", "shortName": "Stock-based Compensation - Restricted Stock and Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dhxd7SBCNU6kU9l8bwFiQg", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_XhFnm-7Gfk6dIdJI0yeiFg", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_XhFnm-7Gfk6dIdJI0yeiFg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Net Loss per Share - Anti-dilutive (Details)", "menuCat": "Details", "order": "34", "role": "http://www.editasmedicine.com/role/DisclosureNetLossPerShareAntiDilutiveDetails", "shortName": "Net Loss per Share - Anti-dilutive (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_XhFnm-7Gfk6dIdJI0yeiFg", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "5", "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_52Zm7EVa5E-k16oWe6xqcQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "6", "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_52Zm7EVa5E-k16oWe6xqcQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SXIbOzTc_06mIIt1-vUxYA", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of Business", "menuCat": "Notes", "order": "8", "role": "http://www.editasmedicine.com/role/DisclosureNatureOfBusiness", "shortName": "Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "edit-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_VDpAf_KAoUqh6yBPaOBnQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 30, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "edit_AccountsReceivableAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of additions to accounts receivable.", "label": "Accounts Receivable, Additions", "terseLabel": "Accounts Receivable, Additions" } } }, "localname": "AccountsReceivableAdditions", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "edit_AccountsReceivableDeductions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of deductions to accounts receivable.", "label": "Accounts Receivable, Deductions", "negatedLabel": "Accounts Receivable, Deductions" } } }, "localname": "AccountsReceivableDeductions", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "edit_AccruedExternalResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to accrued external research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued External Research and Development Expenses, Current", "terseLabel": "External research and development expenses" } } }, "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "edit_AccruedIntellectualPropertyFees": { "auth_ref": [], "calculation": { "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with intellectual property rights.", "label": "Intellectual property and patent related fees" } } }, "localname": "AccruedIntellectualPropertyFees", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "edit_AtMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to at market offering.", "label": "At The Market Offering" } } }, "localname": "AtMarketOfferingMember", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "edit_CollaborativeArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Collaboration and Profit-Sharing Agreements" } } }, "localname": "CollaborativeArrangementsAbstract", "nsuri": "http://www.editasmedicine.com/20230331", "xbrltype": "stringItemType" }, "edit_CommitmentToReimburseLicensorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment to reimburse the licensor for prosecution and maintenance of patent rights pursuant to the license agreement by and among the reporting entity, The Broad Institute Inc. and the Fellows of Harvard College.", "label": "Licensor Expense Reimbursements" } } }, "localname": "CommitmentToReimburseLicensorMember", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementsDetails" ], "xbrltype": "domainItemType" }, "edit_IncreaseDecreaseInRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount represents the increase (decrease) in right of use assets.", "label": "Increase (Decrease) in Right Of Use Assets", "negatedLabel": "Right-of-use assets" } } }, "localname": "IncreaseDecreaseInRightOfUseAssets", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "edit_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment used for research and development.", "label": "Laboratory equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "edit_MarketableSecuritiesNoncurrentNumberOfSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of noncurrent marketable securities held.", "label": "Marketable Securities, Noncurrent, Number of Securities", "terseLabel": "Number of noncurrent securities" } } }, "localname": "MarketableSecuritiesNoncurrentNumberOfSecurities", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "integerItemType" }, "edit_SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of proceeds from common stock agreed to be issued or sold under the agreement.", "label": "Sales Agreement, Amount Of Aggregate Sale Proceeds Of Common Stock Agreed To Be Issued", "terseLabel": "Sales agreement amount of aggregate sale proceeds of common stock agreed to be issued" } } }, "localname": "SalesAgreementAmountOfAggregateSaleProceedsOfCommonStockAgreedToBeIssued", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of account receivable and contract liabilities.", "label": "Schedule of Accounts Receivable and Contract Liabilities Table Text Block", "terseLabel": "Schedule of accounts receivable and contract liabilities" } } }, "localname": "ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsTables" ], "xbrltype": "textBlockItemType" }, "edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of change in contract with customer asset and liability.", "label": "Schedule of Change in Contract with Customer Asset and Liability [Table Text Block]", "terseLabel": "Schedule of change in contract assets and contract liabilities" } } }, "localname": "ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://www.editasmedicine.com/20230331", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r8", "r340" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails", "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional service expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r49", "r89" ], "calculation": { "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r15", "r16", "r17", "r92", "r311", "r319", "r320" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r14", "r17", "r67", "r272", "r315", "r316", "r348", "r349", "r350", "r353", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r2" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r233", "r234", "r235", "r353", "r354", "r355", "r367" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r64", "r65", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive common stock equivalent shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Potentially dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r71", "r74", "r91", "r111", "r142", "r145", "r149", "r158", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r243", "r247", "r260", "r340", "r363", "r364", "r370" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r85", "r93", "r111", "r158", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r243", "r247", "r260", "r340", "r363", "r364", "r370" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r68" ], "calculation": { "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Financial Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r44" ], "calculation": { "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r45" ], "calculation": { "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r155", "r165" ], "calculation": { "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r43", "r154", "r165", "r305" ], "calculation": { "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities, Debt Securities", "terseLabel": "Fair Value", "verboseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails", "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r35", "r36", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Fixed asset additions included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r35", "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Capital Lease Obligations Incurred", "negatedLabel": "Remeasurement of operating lease liabilities and right-of-use assets due to lease modification" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Equivalents and Marketable Securities" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r34", "r87", "r325" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Cash Equivalents and Marketable Securities" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r29", "r34", "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r29", "r69" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r239", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration and Profit-Sharing Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails", "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r52", "r171", "r172", "r321", "r362" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r353", "r354", "r367" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r1", "r54" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r1", "r340" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 68,993,591 and 68,847,382 shares issued, and 68,993,591 and 68,847,382 shares outstanding at March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r18", "r99", "r101", "r106", "r307", "r313" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction-in-progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r187", "r188", "r191" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Deferred Revenue, Balance at End of Period", "periodStartLabel": "Deferred Revenue, Balance at Beginning of Period" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract liabilities, deferred revenue:", "terseLabel": "Contract liabilities:" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r187", "r188", "r191" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r187", "r188", "r191" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r334", "r336", "r374" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate notes/bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails", "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Number of Available for Sale Securities Held in Continuous Unrealized Loss Position Twelve Months or Longer", "terseLabel": "Number of securities in an unrealized loss position for more than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r356" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)", "terseLabel": "Realized gains (losses) on available-for-sale securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r32", "r47" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r201", "r229", "r230", "r232", "r236", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r107", "r117", "r118", "r119", "r120", "r121", "r125", "r127", "r129", "r130", "r131", "r135", "r251", "r252", "r308", "r314", "r327" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r107", "r117", "r118", "r119", "r120", "r121", "r127", "r129", "r130", "r131", "r135", "r251", "r252", "r308", "r314", "r327" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r132", "r133", "r134", "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "verboseLabel": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNetLossPerShareAntiDilutiveDetails", "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r54", "r83", "r102", "r103", "r104", "r112", "r113", "r114", "r116", "r122", "r124", "r137", "r159", "r186", "r233", "r234", "r235", "r237", "r238", "r250", "r261", "r262", "r263", "r264", "r265", "r267", "r272", "r315", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r253", "r254", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r182", "r192", "r193", "r194", "r195", "r196", "r197", "r254", "r276", "r277", "r278", "r331", "r332", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r253", "r254", "r255", "r256", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r182", "r192", "r197", "r254", "r276", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r182", "r192", "r197", "r254", "r277", "r331", "r332", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r182", "r192", "r193", "r194", "r195", "r196", "r197", "r276", "r277", "r278", "r331", "r332", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r257", "r259" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r156", "r157", "r160", "r161", "r162", "r163", "r164", "r166", "r167", "r168", "r183", "r185", "r249", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r330", "r357", "r358", "r359", "r375", "r376", "r377", "r378", "r379", "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails", "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and office equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r32" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r22" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r198", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [ "r198", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r31" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r31" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r31" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r303", "r351" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r351", "r369" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Right Of Use Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r351" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r31" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Statement of Stockholders' Equity (Deficit)" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r23", "r25" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "terseLabel": "Interest income, net" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r10", "r111", "r158", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r244", "r247", "r248", "r260", "r328", "r363", "r370", "r371" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r6", "r72", "r77", "r340", "r352", "r360", "r368" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r12", "r86", "r111", "r158", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r244", "r247", "r248", "r260", "r340", "r363", "r370", "r371" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Marketable securities", "verboseLabel": "Noncurrent marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails", "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails", "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r138", "r139" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flow from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flow from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r29", "r30", "r33" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flow from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r20", "r33", "r73", "r80", "r84", "r97", "r100", "r104", "r111", "r115", "r117", "r118", "r119", "r120", "r123", "r124", "r128", "r142", "r144", "r148", "r150", "r158", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r252", "r260", "r329", "r363" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r24" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income, net:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of changes in unvested restricted stock" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r142", "r144", "r148", "r150", "r329" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r269" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r269" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r270", "r271" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "verboseLabel": "Cash paid in connection with operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r268" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r90" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Restricted cash and other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Commitments and contingencies" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r94", "r95", "r96" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax", "terseLabel": "Unrealized gain (loss) on marketable debt securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r54", "r98", "r101", "r105", "r261", "r266", "r267", "r306", "r312", "r348", "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Unrealized gain (loss) on marketable debt securities" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r26" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r42" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r27" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance based awards" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r0", "r184" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r0", "r184" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r0", "r340" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r347" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r28", "r63" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalAndContractServicesExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.", "label": "Professional and Contract Services Expense", "terseLabel": "Expense for prosecution and maintenance of patent rights" } } }, "localname": "ProfessionalAndContractServicesExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r84", "r97", "r100", "r108", "r111", "r115", "r123", "r124", "r142", "r144", "r148", "r150", "r158", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r242", "r245", "r246", "r252", "r260", "r309", "r329", "r338", "r339", "r350", "r363" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r51", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r48", "r88" ], "calculation": { "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r50", "r79", "r310", "r340" ], "calculation": { "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r78", "r81", "r340" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "periodEndLabel": "Accounts receivable, Balance at End of Period", "periodStartLabel": "Accounts receivable, Balance at Beginning of Period", "terseLabel": "Accounts receivable" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsRevenueRecognitionDetails", "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables, Net, Current [Abstract]", "terseLabel": "Accounts receivable" } } }, "localname": "ReceivablesNetCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCollaborationAndProfitSharingAgreementsRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r66", "r82", "r372" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r34", "r38", "r70", "r75", "r87" ], "calculation": { "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage.", "label": "Restricted Cash and Cash Equivalents, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.", "label": "Restricted Cash and Cash Equivalents [Axis]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restricted Cash and Cash Equivalents Items [Line Items]", "verboseLabel": "Cash Equivalents and Marketable Securities" } } }, "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r3", "r55", "r76", "r318", "r320", "r340" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails", "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r83", "r112", "r113", "r114", "r116", "r122", "r124", "r159", "r233", "r234", "r235", "r237", "r238", "r250", "r315", "r317" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Other Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r140", "r141", "r143", "r146", "r147", "r151", "r152", "r153", "r189", "r190", "r304" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration and other research and development revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.", "label": "Revenue from Contract with Customer, Product and Service [Extensible List]", "terseLabel": "Revenue type" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of anti-dilutive common stock equivalents" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Schedule of cash equivalents and marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r198", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r57", "r58", "r59" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r31" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Issued (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested restricted shares, end of period(in shares)", "periodStartLabel": "Unvested restricted shares, beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Changes in unvested restricted stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Balance, ending of period", "periodStartLabel": "Balance, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Stock-based compensation disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollar per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end of period (in shares)", "periodStartLabel": "Outstanding, beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Changes in unvested stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "periodStartLabel": "Outstanding, beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Employees" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable, aggregated intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable, remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, end of period (in shares)", "periodStartLabel": "Balance, beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r39", "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r13", "r54", "r83", "r102", "r103", "r104", "r112", "r113", "r114", "r116", "r122", "r124", "r137", "r159", "r186", "r233", "r234", "r235", "r237", "r238", "r250", "r261", "r262", "r263", "r264", "r265", "r267", "r272", "r315", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Stockholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r112", "r113", "r114", "r137", "r304" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r0", "r1", "r54", "r55" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of common stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r0", "r1", "r54", "r55" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted common stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r0", "r1", "r54", "r55", "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails", "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r54", "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted common stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r13", "r54", "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r1", "r4", "r5", "r41", "r340", "r352", "r360", "r368" ], "calculation": { "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Liquidity" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash and non-cash activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r156", "r157", "r183", "r185", "r249", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r357", "r358", "r359", "r375", "r376", "r377", "r378", "r379", "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails", "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r326", "r334", "r373" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "Government agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "auth_ref": [ "r334", "r374" ], "lang": { "en-us": { "role": { "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.", "label": "Government agency securities." } } }, "localname": "USStatesAndPoliticalSubdivisionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r326", "r334", "r336", "r373" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U.S. Treasuries" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesDetails", "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r126", "r131" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r125", "r131" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r341": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r342": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r343": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r344": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r345": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r346": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 52 0001558370-23-008308-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-008308-xbrl.zip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end